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Abbreviations 
 
CAI          carbonic anhydrase inhibitor 
CPC          cyclophotocoagulation 
cw             continuous-wave 
ECCE       extracapsular cataract extraction 
EG         exfoliation glaucoma 
fr               free-running 
ICCE         intracapsular cataract extraction 
IOL           intraocular lens 
IOP           intraocular pressure 
J                Joule 
mo             month  
mW           milliwatt 
n.d.            not done 
Nd             neodymium  
Nd:YAG   neodymium:yttrium-aluminium-garnet 
nm             nanometer 
n.s.            not statistically significant 
NVG         neovascular glaucoma 
pc              posterior chamber 
ppv            pars plana vitrectomy 
SD             standard deviation 
VA            visual acuity 
W              Watt 
y year 
YAG          yttrium-aluminium-garnet 
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1. Introduction 
Glaucoma is an ocular disease causing atrophy of the optic nerve head. The chief risk factor of optic nerve 
head damage is intraocular pressure (IOP), and treatment by medication, laser procedures and incisional 
surgery aims at lowering the IOP to a level at which no further damage will occur.  
The IOP is determined by the balance between the production of aqueous humour in the ciliary body and 
the outflow of aqueous humour via the trabecular meshwork and by the uveoscleral pathway. All treatment 
options aimed at lowering the IOP affect one or both of the above.  
Cyclodestruction aims at lowering the IOP by reducing production of the aqueous humour in the ciliary 
body, and alteration of the vascular supply of the ciliary body probably acts as a synergistic mechanism. (van 
der Zypen et al. 1989, Schlote et al. 2001a) Further, experimental studies suggest that cyclodestruction may 
also enhance uveoscleral outflow owing to postoperative inflammation or disruption of the neuroepithelial 
barrier at the level of the pars plana. (Schubert et al. 1989a, Schubert et al. 1990, Liu et al. 1994) 
Cyclodestruction is used in patients in whom IOP cannot be controlled by the maximum tolerable medical 
therapy and in whom filtration surgery is likely to fail, has failed or is not feasible (Mastrobattista et al. 1996, 
Chen et al. 1999), but it has also been proposed as first-line therapy in primary open-angle glaucoma. (Egbert 
et al. 2001) Cyclodestruction rather than filtration surgery, is also used in eyes with limited visual potential 
and for relief of pain in eyes with no visual potential. (Mastrobattista et al. 1996, Stewart et al. 1996, Chen et 
al. 1999) It is used in patients who, for medical reasons, are unable to undergo filtration surgery or in those 
who decline surgical treatment. (Stewart et al. 1996, Chen et al. 1999) Previously, cyclocryocoagulation was 
the means most widely used for cyclodestruction but owing to the high rate of complications and the 
unpredictable effect of treatment, it has fallen into disfavour.    
The first laser widely used for cyclophotocoagulation (CPC), was the 1064 nm Neodymium:YAG 
(Nd:YAG), operating in the pulse mode. However, especially in the long term, the result of the treatment was 
unpredictable, with a high incidence of post-operative pain, hypotonia, phthisis bulbi and visual loss. 
(Schuman et al. 1990a, Trope et al. 1990, Schuman et al. 1992, Al-Ghamdi et al. 1993, Shields et al. 1993, 
Baez et al. 1994, Shields et al. 1994, Dickens et al. 1995, Zhou Wei et al. 1996)  
Later, improvements in the use of the Nd:YAG included employing the laser in the continuous-wave (cw) 
mode, using a longer application time (up to 2 seconds) and a contact probe. However, the theoretical 
disadvantage of the Nd:YAG remained: it is less than optimally absorbed by the melanin in the pars plicata 
of the ciliary body.  
The absorption of light energy by melanin increases with a decrease in wavelength. (Rol et al. 1990) 
Thus, more recently, the 810 nm infrared diode laser has been adopted for CPC. The 647 nm krypton and the 
670 nm diode red lasers have an even higher affinity for the pigment epithelium, and thus are more 
selectively absorbed by the target tissue than the infrared Nd:YAG and the 810 nm diode lasers. It has been 
shown that the red krypton laser, with poorer scleral transmission, but better absorption by the pigment 
epithelium than the Nd:YAG, produced more cyclodestruction at similar power settings. (Immonen et al. 
1993) Furthermore, the long application time, 10 seconds, of red laser CPC allows the use of very low 
intraocular power levels as compared with the laser modalities previously used for CPC. 
This study was designed to examine the usefulness of and the complications with the red 647 nm krypton 
laser for CPC in the treatment of the difficult posttraumatic glaucoma and of refractory glaucoma in children 
and young adults. The combination of red laser CPC with limited anterior retinal cryocoagulation was 
studied in recalcitrant neovascular glaucoma. The effect of red laser CPC on the corneal innervation and the 
parameters related to it was also studied in eyes undergoing 670 nm diode CPC.  
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2. Review of the literature 
2.1. Glaucoma  
2.1.1. Definition  
Glaucoma is an optical neuropathy characterized by a specific pattern of damage to the optic nerve head and 
the visual field, which represents the final common pathway resulting from various conditions that can affect 
the eye. (Ritch et al. 1996). 
2.1.2. Treatment options 
Treatment is currently aimed at reducing the IOP to an individual target pressure. This is achieved by 
medical therapy, laser treatment or incisional surgery.  
Medical therapy lowers the IOP by decreasing the production of aqueous humour, by increasing the 
conventional outflow of the aqueous humour, and also by increasing its outflow via the uveoscleral route. In 
patients who are not helped by the maximal tolerated glaucoma medication, argon laser trabeculoplasty 
(Wise et al. 1979) is performed to obtain further reduction of IOP by increasing the facility of aqueous 
outflow. Trabeculectomy (Cairns 1968), with its numerous modifications, produces a guarded fistula 
between the anterior chamber and the subconjunctival space. (Traverso et al. 1987) It is used in cases where 
non-invasive therapy has failed, or is unsuitable (e.g. when compliance with medical therapy is a problem), 
when appropriate medical therapy is not available, or when the target pressure required cannot be reached 
with medications or laser treatment, and when the IOP is so high at presentation that other forms of therapy 
are unlikely to be successful. (Watson et al. 1981, Jay et al. 1988, Migdal et al. 1994) In selected cases, to 
prevent postoperative conjunctival scarring with resultant failure of filtration and to reach a low target 
pressure, antimetabolites are used at the site of trabeculectomy. (Khaw et al. 1996)  
The use of glaucoma implant surgery is generally reserved for patients in whom filtering surgery with 
antimetabolites has failed or for patients with excessive conjunctival scarring due to previous surgery, who 
have a very high risk of failure of trabeculectomy or where filtration surgery would have been technically 
difficult. (Fellenbaum et al. 1994, Coleman et al. 1995, Mills et al. 1996) Future research will establish the 
place of non-penetrating filtration procedures, such as deep sclerectomy and viscocanalostomy, in the field 
of glaucoma surgery. (Schwenn et al. 1998, Stegmann et al. 1999, Mermoud et al. 1999) 
The aim of cyclophotocoagulation is to reduce the production of aqueous humour by ablating the 
epithelium of the ciliary processes in the pars plicata of the ciliary body. (Beckman et al. 1972, Schuman et 
al. 1990b, Liu et al. 1994, Stewart et al. 1996). The conventional role of transscleral cyclophotocoagulation 
has been in those refractory cases in which all other treatments, including incisional surgeries, have been 
tried and have failed (Wilson 2001, Semchyshyn et al. 2002) Patients typically are those who have a high 
IOP that cannot be controlled by medication or previous surgery, or who would be poor surgical candidates 
or who decline surgical treatment. (Chen et al. 1999) Cyclodestruction, instead of filtration surgery, is also 
used in eyes with limited visual potential and for relief of pain in eyes with no visual potential. 
(Mastrobattista et al. 1996, Stewart et al. 1996, Chen et al. 1999)  
  Review of the literature 
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2.2. Cyclodestruction  
2.2.1. The pre-laser era of cyclodestruction 
 
Cyclodestruction aims at causing atrophy in the secretory non-pigmented ciliary epithelium of the pars 
plicata of the ciliary body and thus reducing the production of aqueous humour. (Stewart et al. 1996) The 
early cyclodestructive procedures included non-penetrating cyclodiathermy introduced by Weve in 1933 
(Weve 1933), penetrating cyclodiathermy developed by Vogt in 1936 (Vogt 1936), and cycloelectrolysis 
evaluated by Berens in 1949 (Berens et al. 1949). In 1950, Bietti suggested freezing as a method for 
producing ciliary body damage. (Bietti 1950) Krwawicz studied the action of low temperature on various 
ocular structures, including the ciliary body. (Krwawicz 1966) DeRoetth reported that cyclocryotherapy was 
effective in treating patients with open-angle glaucoma. (DeRoetth 1968) In a study by Bellows et al. in 
1973, approximately 75% of patients with open-angle glaucoma followed for more than a year had IOPs of 
19 mmHg or less. (Bellows et al. 1973)  
In 1985, Shields reported that cyclocryocoagulation resulted in adequate pressure control in 64% of 
neovascular glaucomatous eyes, but that 17% progressed to phthisis bulbi and 69% had profound loss of 
visual acuity (VA). (Shields et al. 1985) Also, because of the postoperative pain and the significant incidence 
of postoperative inflammation, which occasionally leads to extensive posterior synechiae and chronic flare 
(Stewart et al. 1996), this treatment has fallen into disfavour despite attempts to modify the procedure in 
order to reduce the complications. (Lehtinen et al. 1968)  
2.2.2. Cyclophotocoagulation 
History 
 
In 1961, Weekers et al. employed light as the cyclodestructive element, using the transscleral application of 
xenon arc photocoagulation over the ciliary body. (Weekers et al. 1961) However, it was the introduction of 
the laser, a source of monochromatic and coherent light, that eventually led to the clinical application of 
cyclophotocoagulation.  
In 1969, Smith and Stein, and Vucicevic et al. reported the use of the first laser CPC, using a ruby and a 
neodymium (Nd) laser in rabbits. (Smith et al. 1969, Vucicevic et al. 1969) In human subjects, Beckman et 
al. reported the use of the ruby laser for transscleral CPC in 1972, that of the Nd:glass in 1973, and that of 
the 1064 nm Nd:YAG in 1985. (Beckman et al. 1972, Beckman et al. 1973, Beckman 1985) It was only after 
the better availability of the Nd:YAG laser that the use of CPC became widespread.  
The Nd:YAG laser can be used for CPC in a free-running thermal mode, which is delivered in short 
pulses, or in a continuous-wave mode, in which the laser emits radiation continuously over time. (Stewart et 
al. 1996) In the beginning of the previous decade, the use of the cw-810 nm diode laser for CPC began. 
(Balles et al. 1990, Naguib et al. 1990, Assia et al. 1991, Brancato et al. 1991, Hennis et al. 1992) The 810 
nm diode laser incorporates two light-emitting diodes with a combined wavelength of 810 nm. (Stewart et al. 
1996) Most recently, the cw-647 nm krypton (Immonen et al. 1994, Kivelä et al. 1995) and the cw-670 nm 
diode (Immonen et al. 1996) have been adopted for CPC.  
 
Laser delivery to the ciliary body 
 
Laser energy can be delivered to the ciliary body by various routes. The laser beam emitted from a slit-lamp 
delivery system travels through air and through the sclera to reach the target tissue. This so-called 
Review of the literature 
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transscleral non-contact method has nowadays mostly been abandoned. The method most widely used today 
is the transscleral contact method, in which the laser light is delivered via a fibreoptic probe which is placed 
on the sclera. When circumstances allow for the visualization of the ciliary processes, cyclophotocoagulation 
can also be performed by delivering laser energy across the plane of the pupil (Kim et al. 1999) or by using 
an intraocular endolaser with or without an endoscope. (Shields et al. 1985, Pastor et al. 2001) 
 
Scleral transillumination  
 
To achieve ablation of the ciliary processes by transscleral cyclophotocoagulation, it is important to place the 
laser beam in a correct location over the ciliary body. (Hampton et al. 1988, Allingham et al. 1990, Brancato 
et al. 1990, Schuman et al. 1991, Bloom et al. 1992, Marsh et al. 1993, Brancato et al. 1994) The site of the 
ciliary body is not uniform for all eyes, and the position in relation to the limbus may vary with the axial 
length. (Frieling et al. 1995) Thus, scleral transillumination (Sharkey et al. 1994) is recommended to locate 
the anterior edge of the ciliary processes. Transillumination is reported to be used routinely in every case 
deemed to be an important step. (Bloom et al. 1997, Mistlberger et al. 2001, Kirwan et al. 2002) Some 
surgeons, however, limit the use of scleral transillumination to cases with atypical ciliary body anatomy, 
such as occurs in congenital glaucoma, or to those with anatomic limbal abnormalities. (Bock et al. 1997, 
Spencer et al. 1999) 
 
Non-contact CPC 
 
Non-contact Nd:YAG laser CPC is delivered without the use of a contact probe with the patient sitting at the 
laser slit lamp. A contact lens can be used to blanch the conjunctiva, but no histological difference was found 
in the ciliary body lesion when a contact lens was used as compared with a treatment without it. (Simmons et 
al. 1990). The most effective destruction of the pars plicata was achieved with applications located 1 to 1.5 
mm behind the limbus (1 mm temporally and nasally and 1.5 mm superiorly and inferiorly), using an energy 
of 7 to 8 J. (Hampton et al. 1988) Lower IOPs were achieved with fewer retreatments in eyes treated at 1.5 
mm instead of 3 mm posterior to the limbus. (Crymes et al. 1989) No substantial difference in the gross 
appearance of the lesions was noted between the tangential and perpendicular approaches for the same 
treatment distance. (Hampton et al. 1988) 
The treatment guidelines published by Schuman and Puliafito recommend a 360° treatment with 8 
applications per quadrant, sparing the 3 o´clock and 9 o´clock positions, with an energy of 8 J, an application 
time of 20 ms, and maximum offset. (Schuman et al. 1990a) The parameters remain the same for the 
retreatment, except that the number of applications should be half the previous number. Comparison of initial 
treatments at 180° and 360° showed that control of IOP was achieved more slowly with the 180-degree 
treatment, which required more treatment sessions, but that the final IOP results in the two groups were 
similar. (Hardten et al. 1993) 
 
Contact CPC 
 The contact  probe 
 
Contact CPC is delivered with a fibreoptic probe, which eliminates the problems of aiming and focusing 
encountered with the non-contact method. The G-probe (Iris Medical Instruments Inc; Mountain View, CA, 
USA) with a 600 µm fibre, a curved footplate to match the scleral curvature, and a 0.7 mm protrusion of the 
fibre-optic tip beyond the contact surface indenting the conjunctiva and sclera, and enhancing laser 
transmission, is widely used for 810 nm diode CPC. (Gaasterland et al. 1992, Kosoko et al. 1996, Bloom et 
al. 1997, Spencer et al. 1999, Egbert et al. 2001, Mistlberger et al. 2001, Schlote 2001b, Kirwan et al. 2002) 
The probe is designed so that the distance from the surgical limbus need not be measured. (Mastrobattista et 
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al. 1996) When the probe is placed at the limbus, the laser beam is directed at a distance of 1.2 mm posterior 
to the limbus, parallel to the visual axis. (Kosoko et al. 1996) The applications can be spaced at half the 
width of the 2-mm G-probe tip by aligning the lateral edge of the probe on the centre of the last application. 
This technique produced burns located in the ciliary processes, as seen in autopsy eyes. (Gaasterland et al. 
1992, Feldman et al. 1997)  
Brancato et al. published a fibre-optic delivery system with a 365 µm fibre and a contact probe with a 3 
mm tip placed tangentially to the corneoscleral limbus, thus centering the laser beam at a predetermined 
distance of 1.5 mm posteriorly from the limbus. (Brancato et al. 1994) This probe is adapted for both 
Nd:YAG and 810 nm diode CPC. For Nd:YAG CPC, Bloom et al. used a rounded, 1.5-mm, tipped probe. 
(Bloom et al. 1992) For CPC with the 647 nm krypton laser, a 1000 µm fibre and a contact probe with a 
1200 µm ball tip were used. (Immonen et al. 1994). 
  
Contact Nd:YAG laser CPC 
 
The technique described by Brancato et al. produced well-defined cyclophotocoagulation as shown by 
histological examinations: the authors recommended that the energy should not be higher than 5 to 6 J. 
(Brancato et al. 1994) Bloom et al. used 5 J, performed transillumination of the eye to determine the location 
of the ciliary body, and placed the anterior edge of the laser probe perpendicularly on the sclera to 
correspond to the anterior edge of the illuminated ciliary body. (Bloom et al. 1992) Histological observations 
in the same study showed that placing the probe at an angle as little as 15° off the perpendicular led to 
destruction of less than optimal sites (Bloom et al. 1992) Along with probe orientation and the distance from 
the limbus, the amount of pressure applied with the contact probe should be kept stable in order to minimize 
the variation in coagulation intensity and lesion size. (Fankhauser et al. 1992, Echelman et al. 1995)  
In contact CPC, less energy is needed than in non-contact laser use. The treatment guidelines published 
by Schuman and Puliafito recommend a 360° treatment with 8 applications per quadrant, sparing the 3 
o´clock and 9 o´clock positions, with a power of 7 W and an application time of 0.7 s. (Schuman et al. 
1990a) The parameters for the retreatment remain the same, except that the number of applications should be 
half of the original number.  
  
Contact 810 nm diode laser CPC 
  
The technique of the contact 810 nm diode laser CPC is similar to that of the contact Nd:YAG laser CPC. 
(Mastrobattista et al. 1996) Currently used treatment parameters include a power of 1.25 to 3 W, an 
application time of 1.5 to 2 s and a total of 10 to 40 applications, usually sparing the 3 o´clock and 9 o´clock 
positions. (Kosoko et al. 1996, Bloom et al. 1997, Spencer et al. 1999, Egbert et al. 2001, Schlote et al. 
2001b) It is common to perform 360° treatments, although some authors recommend sparing one or two 
quadrants of the ciliary body to avoid hypotonia. (Kosoko et al. 1996, Spencer et al. 1999) The number of 
applications and degrees treated can also be individualized according to each case (Bloom et al. 1997, Yap-
Veloso et al. 1998) The parameters and the extent of treatment may remain the same or may be reduced for 
the retreatment (Bloom et al. 1997, Yap-Veloso et al. 1998), or a different 90° from that in the initial 
treatment is left untreated. (Spencer et al. 1999) 
 
Contact Red Laser CPC 
 
The protocol of the contact red laser CPC is described in detail in this book in the Methods -section on page 
32.  
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Laser transmission and absorption 
 
The effect of CPC depends on the absorption of the transmitted laser energy by the melanin granules, which 
are highly concentrated in the pigment epithelium of the ciliary body (Beckman et al. 1972, Cantor et al. 
1989, Schubert et al. 1989b) The energy absorbed is degraded into heat, which leads to thermal damage 
resulting in the denaturation of proteins and inactivation of enzymes. (Vassiliadis 1989)  
Transscleral irradiation must travel through the conjunctiva, the sclera, and the highly vascularized ciliary 
muscle before reaching the ciliary pigment epithelium. When the laser wavelength is well transmitted and at 
the same time effectively absorbed by the ciliary pigment epithelium, the desired interactions can be 
obtained at the target site with minimal effects elsewhere. (Vassiliadis 1989) When the sclera is thinned 
pathologically, transmission is better and will result in exaggerated effects and vice versa. (Rol et al. 1990, 
Kirwan et al. 2002)  
Absorption of laser energy by melanin takes place in pigmented cells, which are found particularly on the 
inner scleral surface (lamina fusca) (Vogel et al. 1991), by the melanin in the pigmented lesions in the 
conjunctiva, by the melanin dispersed throughout the ciliary muscle, and by the melanin in the ciliary body 
pigment epithelium. (Nemati et al. 1996). The role of tissue pigmentation in cyclodestruction was 
demonstrated both experimentally and in enucleated human eyes previously treated with 
cyclophotocoagulation. (Cantor et al. 1989, Ferry et al. 1995) No visible histopathological effect was 
detected after non-contact pulsed Nd:YAG CPC in albino rabbit eyes where there was minimal or no 
pigmentation of the ciliary body stroma or ciliary epithelium. (Cantor et al. 1989) In contrast, in Dutch-
belted rabbit eyes, where there was heavy pigmentation of both the ciliary body stroma and pigmented ciliary 
epithelium, there was marked destruction of the ciliary body after CPC performed at similar energies in the 
same study.  
With an increase in laser wavelength, transmission through the sclera increases and scleral scattering 
decreases (Figure 1). (Rol et al. 1990, Vogel et al. 1991) If contact application is used and pressure is applied 
to the sclera by the fibre-optic probe, scleral transmission is increased and scleral scattering is reduced 
(Figure 2). (Rol et al. 1990, Vogel et al. 1991) The absorption of laser energy by melanin decreases with 
increasing wavelength in the infrared region (Figure 3). (Vassiliadis et al. 1989) The lasers with better 
absorption by the pigment epithelium produce more cyclodestruction at similar power settings, despite their 
poorer scleral transmission, as compared with those more efficiently transmitted but less efficiently 
absorbed. (Assia et al. 1991, Brancato et al. 1991, Immonen et al. 1993)  
 
 
 
  
Figure 1. Total reflection, 
absorption, and transmission of 
the human sclera, plotted as a 
function of laser wavelength. 
The error bars represent the 
standard deviation of the 
measurement values. (From: 
Vogel et al. Optical properties 
of human sclera, and their 
consequences for transscleral 
laser applications. Lasers Surg 
Med 1991;11:334.) 
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Figure 2. Ratio of the scleral 
transmission values with and 
without fibre contact, plotted as 
a function of laser wavelength. 
The ratio was determined for 
gentle and firm pressure of the 
fibre tip against the scleral 
surface. (From: Vogel et al. 
Optical properties of human 
sclera, and their consequences 
for transscleral laser 
applications. Lasers Surg Med 
1991;11:334.) 
 
 
 
Figure 3. Ocular media 
transmission and absorption of 
the retinal pigment epithelium 
and choroid. (From: Vassiliadis 
A. Laser sources and ocular 
effects. In: L´Esperance FA. 
Ophthalmic Lasers, 3rd ed. 
St.Louis: C.V. Mosby Company, 
1989.) 
 
 
 
Mechanisms of IOP decrease 
 
The accepted aim of CPC is ablation of the epithelium of the ciliary processes in the pars plicata of the 
ciliary body to reduce the production of aqueous humour. (Beckman et al. 1972, Schuman et al. 1990a, Liu et 
al. 1994, Stewart et al. 1996). However, transscleral and transpupillary photocoagulation of the pars plana or 
an even more posterior site was also shown to decrease the IOP in the rabbit, the monkey, and the human eye 
(Schiødte 1982, Schubert et al. 1989a, Liu et al. 1994) Non-contact Nd:YAG laser photocoagulation of the 
pars plana increased the outflow in enucleated human and porcine eyes, which was considered to relate to the 
pars plana transscleral outflow, facilitated by disruption of the neuroepithelial barrier. (Schubert et al. 1990) 
In monkeys, coagulation of the pars plana with the contact Nd:YAG laser resulted in enhancement of 
uveoscleral outflow, which was not demonstrable after pars plicata coagulation in the same study. (Liu et al. 
1994) The increase in the outflow facility after cyclocryocoagulation supports the view that non-
conventional outflow pathways are increased after cyclodestruction. (Duy et al. 1987) 
In the monkey eye, contact Nd:YAG laser photocoagulation at the equator produced a decrease in IOP 
which was closely related to the breakdown of the blood-ocular barrier observed as flare (Schubert et al. 
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1989a), and contact Nd:YAG CPC either in the pars plicata or in the pars plana produced a significant 
decrease in IOP corresponding to the degree of inflammation in the anterior chamber. (Liu et al. 1994) 
Inflammatory mediators such as prostaglandin F2α enhance aqueous drainage via the uveoscleral pathway 
(Crawford et al. 1987) and are currently also adopted for therapeutic use in glaucoma.  
 The alteration of ciliary body vascularization demonstrated after contact 810 nm diode laser CPC 
probably acts as a synergistic mechanism for decreasing IOP. (Pablo et al. 1997, Schlote et al. 2001a) 
 
Morphological changes observed in the cil iary body epithelium, the stroma and the 
ciliary body vasculature  
 
The Nd:YAG laser 
 
With pulsed Nd:YAG CPC, energy levels ranging from 4.4 to 9 J were effective in producing appropriate 
lesions in the ciliary body. A blister-like elevation of the ciliary epithelium was described early after 
treatment. (Devenyi et al. 1987, Hampton et al. 1988, Blasini et al. 1990, Ferry et al. 1995) Destruction of the 
non-pigmented and pigmented epithelium was seen and the pigmented epithelium was more vulnerable to 
laser energy. (Marsh et al. 1993, Ferry 1995 et al.) In the peripheral zones of individual treatment sites, the 
epithelium lining the crests of the ciliary processes survived the treatment, in contrast to the valleys between 
the crests. Hyperplasia of the non-pigmented epithelium occurred later. (Marsh et al. 1993) Occlusion of the 
capillaries of the ciliary processes was also detected. (Marsh et al. 1993) 
A videographic recording technique and light microscopy were used in a study comparing tissue 
responses to three Nd:YAG lasers with different durations of exposure, modes of laser, and various energy 
levels: a pulsed contact laser with a duration of 0.75 ms; a pulsed non-contact laser with a duration of 20 ms; 
and a continuous-wave contact laser with durations of 700 and 2000 ms. (Prum et al. 1992) Both pulsed 
lasers caused mild whitening of the pigment epithelium with frequent vapourization and explosive tissue 
disintegration, typically most marked with the 0.75-ms pulsed laser. In contrast, the continuous-wave laser 
produced prominent tissue whitening and puckering, seen histologically as convolution of the epithelium and 
coagulation of the stroma, called a shrinkage-like lesion. (Prum et al. 1992)  
 
The 810 nm diode laser 
 
In gross examination of human cadaver eyes, the transscleral non-contact 810 nm diode laser caused 
homogeneous blanching of the ciliary processes and ciliary body shrinkage at an energy of 1.2 J. (Hennis et 
al. 1991) Using a transscleral contact technique, the 818 nm or the 850 nm diode laser produced no visible 
damage to the ciliary body at exposures of less than 2 J in human autopsy eyes. (Schuman et al. 1991) A 2 to 
3 J exposure produced mild whitening and 4 to 5 J exposures more intense whitening of the pars plicata. 
Energies higher than 5 J frequently produced explosive tissue damage. (Schuman et al. 1991) With the use of 
ultrasound in living eyes, detachment of the ciliary body was observed in the early postoperative period. 
(Werner et al. 1998) 
Microscopically, transscleral contact 810 nm diode CPC at an energy level of 3.9 and 5.2 J resulted in 
moderate thermal damage to the ciliary body and coagulative necrosis of the ciliary pigmented and 
unpigmented epithelial layers in a human eye treated shortly before a planned enucleation. (Brancato et al. 
1994) At 7.8 J of energy, wide disorganization of the ciliary processes and marked thermal coagulation of the 
ciliary body bulk with vacuolization and swelling of collagen fibres were noted. (Brancato et al. 1994) With 
the contact 818 nm and the 850 nm diode CPCs, evidence of thermal coagulation of the ciliary body stroma 
and stromal vasculature was found and coagulation necrosis was more intense with longer exposure times. 
(Schuman et al. 1991) At 4 to 5 J, disruption of the pigmented and non-pigmented epithelium and intense 
coagulation of the ciliary body stroma were seen. Marked rarefication in the capillary network within the 
treatment areas in the pars plicata and pars plana was demonstrated using vascular casts in the rabbit after 
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transscleral contact 810 nm diode laser. (Schlote et al. 2001a) Thermal coagulation of the stromal vasculature 
was also histologically evident in the rabbit after transscleral contact 810 nm diode laser. (Pablo et al. 1997)  
During continuous-wave laser application, an audible pop is produced when the threshold between 
coagulation and explosive tissue disintegration is exceeded, representing an intraocular uveal micro- 
explosion. (Prum et al. 1992) Audible pops are associated with more severe postoperative inflammation and 
increased risk of postoperative hyphema. (Rebolleda et al. 1998) Investigations concerning dosage problems 
of transscleral CPC aim at finding a more suitable clinical method for evaluating the amount of laser-induced 
tissue destruction. (Preußner et al. 1997, Rosenow et al. 1999) 
 
The Visible Red Lasers 
 
The transscleral contact 647 nm krypton laser at 0.25 to 0.5 J in the rabbit eye produced thinning of the 
pigmented and non-pigmented layers of the ciliary body and some extracellular dispersion of pigment 
granules. (Immonen et al. 1993) At higher energies in the same study, more widespread destruction was 
detected, with occasional bleeding under the ciliary body. These findings were similar to the continuous-
wave Nd:YAG lesions at approximately double the energy in the same study. Autopsy findings in an eye 
treated with the transscleral contact 647 nm krypton laser CPC at 3.7 J (power 0.37 W and duration of 
application 10 s) showed confluent scars straddling the posterior pars plicata and the anterior pars plana, and 
the posterior processes had totally disappeared. (Kivelä et al. 1995) Dispersed pigment engulfed by 
clumplike cells was abundant within the subepithelial stroma. 
 The transscleral contact 670 nm diode laser in the rabbit eye at 0.5 to 1 J (0.2 W, 2.5 and 5 s, 
respectively) produced grey discoloration of the ciliary body epithelium with some shrinkage of the ciliary 
processes. (Immonen et al. 1996) Histological examination demonstrated the disappearance of the non-
pigmented and pigmented epithelium and pigment dispersion in the photocoagulated areas. The histological 
changes observed recently after use of a clinical 670 nm diode laser CPC at 4.3 J (power 0.43 W and 
duration of application 10 s) in a human eye are essentially identical to those decribed after use of a clinical 
transscleral contact 647 nm krypton laser CPC at 3.7 J. (Kivelä et al. 1995, Tarkkanen 2001, personal 
communication, to be published) 
 
Morphological changes observed elsewhere  
The conjunctiva 
 
In the conjunctiva, white lesions that fade within 24 to 48 hours appear at the site of laser application after 
the use of the clinical non-contact Nd:YAG CPC (Schuman et al. 1990a, Shields et al. 1994). With use of the 
contact lens, these conjunctival burns are smaller and tissue disruption is rare. (Shields et al. 1994) Following 
contact Nd:YAG CPC, the treated eye generally shows less conjunctival coagulation. (Schuman et al. 1990a) 
Mild burns on the conjunctival surface resolving 24 hours to one week after treatment are described after 
contact 810 nm diode CPC. (Kosoko et al. 1996, Bloom et al. 1997, Gupta et al. 1997, Schlote et al. 2001b, 
Kirwan et al. 2002) No signs of conjunctival burns were seen after transscleral contact 647 nm krypton CPC. 
(Immonen et al. 1994)  
 
The sclera 
 
Scleral reactions have been produced at energies above those producing a desired effect in the ciliary body 
epithelium in experimental cyclophotocoagulation in cadaver eyes (Schuman et al. 1991), in a human eye 
that was soon to be enucleated (Brancato et al. 1994), and in the rabbit eye. (Immonen et al. 1993) Heat-
induced homogenization of the scleral lamellae near the damaged ciliary body occurred after both contact 
transscleral Nd:YAG and contact transscleral 810 nm diode laser treatment at 6.6 J, an amount of energy 
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above the recommended level. (Brancato et al. 1994) Superficial scleral damage was observed after contact 
transscleral 818 nm and 850 nm diode laser treatment at a high energy of 8 J. (Schuman et al. 1991) In the 
rabbit, with a thinner sclera than that of the human eye, the 810 nm diode laser, with a lower energy of 1.8 J 
per application, produced scleral coagulation at the treatment site. (Pablo et al. 1997) After the transscleral 
contact 647 nm krypton and the cw-Nd:YAG CPC in rabbits, oedema and cell infiltrates were detected in the 
sclera at the site of the lesions produced by energies above 1 J. (Immonen et al. 1993) Defocusing the non-
contact pulsed Nd:YAG laser progressively less than the maximum of 9 was associated with progressively 
greater tissue disruption on the external surface of the sclera. (Hampton et al. 1988)   
After a failed clinical non-contact pulsed Nd:YAG CPC, (Marsh et al. 1993) and a failed clinical contact 
810 nm diode CPC, (Walland et al. 1998), no evidence of scleral damage was present on examination of 
enucleated eyes. In a larger histopathological series of nine eyes treated with contact 810 nm diode CPC, 
scleral scarring was detected in three eyes. (McKelvie et al. 2002) Focal areas of oedema in the deep sclera 
were observed in one study of eyes enucleated after non-contact pulsed Nd:YAG CPC. (Ferry et al. 1995) In 
a previously treated human autopsy eye, the krypton laser was shown to produce clinically efficient 
cyclophotocoagulation without histopathological scleral damage. (Kivelä et al. 1995)  
Clinically, focal scleral thinning was detected in a 30-year-old patient treated with the non-contact 
Nd:YAG laser CPC.  (Fiore et al. 1989) More recently, scleral perforation was reported after 810 nm contact 
CPC in an eye with scleral thinning following cataract surgery. (Sabri et al. 1999) Further, scleral 
staphyloma developed in an eye with a previous posterior pole choroidal melanoma, and focal thinning of the 
sclera was noted in a previous sclerotomy site after 810 nm contact CPC. (Bhola et al. 2001) 
 
The ci l iary muscle 
 
The ciliary muscle and the inner connective tissue layer of the ciliary body were markedly atrophic in an 
autopsy eye previously treated with transscleral contact 647 nm krypton laser CPC. (Kivelä et al. 1995) Loss 
of some of the inner layers of the ciliary muscle also developed after clinical non-contact pulsed Nd:YAG 
CPC, but there was a moderate amount of haemorrhage within the central layers of the ciliary muscle. 
(Marsh et al. 1993) In another study of eyes enucleated after non-contact pulsed Nd:YAG CPC, the ciliary 
muscle was always severely damaged. (Ferry et al. 1995)  
When the tissue responses of the cw contact Nd:YAG laser and the cw contact 810 nm diode laser were 
videographically and histologically compared, the Nd:YAG produced coagulation and disruption of the 
ciliary epithelium and little effect on the underlying ciliary muscle, whereas the 810 nm diode laser had less 
effect on the ciliary epithelium but caused a significant coagulative response in the ciliary muscle. (Simmons 
et al. 1994) However, the laser power was 2 to 3 times higher in the Nd:YAG-treated eyes, although a 
similar application time of 2 seconds was used in both laser modalities. In enucleated eyes that had been 
previously treated with the 810 nm diode CPC, the ciliary muscle was extensively destroyed. (McKelvie et 
al. 2002) 
 
The iris ,  the lens, the intraocular lens and the zonules  
 
The peripheral iris was affected, when tangentially or perpendicularly oriented non-contact pulsed Nd:YAG 
at 4 to 8 J was performed at 0.5 mm from the limbus in human autopsy eyes. (Hampton et al. 1988) When 
contact 818 nm and 850 nm diode CPC at 2.7 J were performed in human cadaver eyes, placing the probe 
perpendicularly with its anterior edge 0.5 mm posterior to the limbus, focal disruption of the posterior 
pigment epithelium of the peripheral iris resulted. (Schuman et al. 1991) In this position, exposure times of 3 
seconds or longer produced an iridectomy with focal disruption of the lens capsule. Clinically, anterior 
displacement of the laser beam can result in peripheral iris damage (McKelvie et al. 2002) and subsequent 
pupillary distorsion. (Schlote et al. 2000, Bhola et al. 2001) These observations further emphasize the 
importance of careful orientation and location of the ciliary processes with scleral transillumination.  
In contrast, no significant thermal effect at the intraocular lens (IOL) haptic or the capsular bag in 
pseudophakic eyes or on the crystalline lens in phakic eyes was seen in cadaver eyes when a 780 to 830 nm 
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non-contact diode laser was applied perpendicularly at 0.5, 1, or 2 mm from the limbus. (Hennis et al. 1991). 
In that study, the power used was 1.0 to 1.2 W and the pulse duration 0.7 to 1.0 s, resulting in a low total 
energy of 0.7 to 1.2 J. In two experimental studies of noncontact Nd:YAG CPC, IOL haptic damage occurred 
only at the maximum energy of 8.8 J delivered 1 mm posterior to the limbus (Blomquist et al. 1990, Assia et 
al. 1991) The krypton CPC with its long duration of 10 s and power of 0.37 W, performed on the ciliary 
processes at approximately 2 mm from the limbus as determined by transillumination, produced no damage 
to the lens, the iris, the anteriormost ciliary processes or the adjacent zonules. (Kivelä et al. 1995) 
 
Sympathetic ophthalmia 
 
There are few occasional case reports of sympathetic ophthalmia after non-contact and contact Nd:YAG 
CPC in the literature. (Edward et al. 1989, Brown et al. 1990, Lam et al. 1992, Pastor et al. 1993, Bechrakis 
et al. 1994) However, in all the reported cases with histological confirmation of sympathetic ophthalmia, the 
exciting eye had previously undergone incisional surgery (trabeculectomy or cataract extraction) or 
cyclocryocoagulation, all of which are possible exciting events triggering sympathetic ophthalmia. (Sabates 
1988, Minckler 1989) 
  
The retina 
 
Retinal detachment was reported in one adult patient after non-contact Nd:YAG CPC. (Geyer et al. 1993) 
However, two cyclocryocoagulations had already been performed previously in this eye. In children, retinal 
detachment and subsequent phthisis in the majority of the same cases were discovered in 4% to 10% of eyes 
after contact Nd:YAG CPC (Phelan et al. 1995) and 810 nm diode CPC. (Bock et al. 1997, Izgi et al. 2001, 
Kirwan et al. 2002)  
 
Mechanisms of treatment failure 
 
Ciliary epithelial regeneration, reversal of increased uveoscleral outflow, reversal of inflammation, and 
revascularization of the ciliary body (van der Zypen et al. 1989, Schlote et al. 2001a) have been investigated 
in order to explain the gradual recovery of IOP in a proportion of the patients treated with CPC. 
Moderate hyperplasia of the non-pigmented and pigmented ciliary epithelium was noted in an eye 
enucleated 8 weeks after a failed non-contact pulsed Nd:YAG CPC. (Marsh 1993) In the treatment areas, the 
epithelium was spindle-shaped and multilayered.  
Evidence of epithelial regeneration was found in one eye studied by Walland et al., who examined two 
eyes enucleated after a previous failed contact 810 nm diode laser CPC. (Walland et al. 1998) The 
regenerated epithelium was presumed from its appearance to be nonfunctional, and no histological 
explanation for the rise in IOP was provided. In one of these eyes, the laser was delivered too posteriorly, 
and the short-lived IOP reduction probably represented the reversal of an early increase in uveoscleral 
outflow. (Walland et al. 1998)  
Examination of vascular casts of the rabbit ciliary body 12 weeks after contact 810 nm diode CPC 
showed short vessel sprouts at the margins of the laser burns in the pars plana and the pars plicata. (Schlote 
et al. 2001a) With a similar technique, regeneration of the capillary network was observed seven months 
after Nd:YAG CPC in the rabbit eye, but regeneration was mostly incomplete (van der Zypen et al. 1989). 
Further studies are needed to investigate the vascular regeneration process during longer periods of 
observation. (Schlote et al. 2001a) 
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Clinical outcome of cyclophotocoagulation 
Heterogeneous glaucoma population 
 
In unselected glaucoma patients after the 810 nm diode laser CPC, success rates of 48% to 85% have been 
obtained (Table 1). (Kosoko et al. 1996, Bloom et al. 1997, Wong 1997 et al. Werner et al. 1998, Yap-
Veloso et al. 1998, Spencer et al. 1999, Threlkeld et al. 1999, Mistlberger et al. 2001,  Schlote et al. 2001b) 
Comparable success rates (71% to 87%) have been reported after operations with a glaucoma drainage 
device performed in similar patients with glaucoma. (Airaksinen et al. 1990, Noureddin et al. 1992, Lloyd et 
al. 1994, Välimäki et al. 1998, Krishna et al. 2001) With the Nd:YAG CPC, performed with either the non-
contact or the contact method, the success rate was 39% to 79% (Brancato et al. 1989, Hampton et al. 1990, 
Schuman et al. 1992, Al-Ghamdi et al. 1993, Hawkins et al. 1993). With the contact krypton CPC, success 
was achieved in 73% of eyes. (Immonen et al. 1994)  
Hypotonia rates of 0% to 15%, (Brancato et al. 1989, Schuman et al. 1990c, Al-Ghamdi et al. 1993, 
Shields et al. 1994) and rates of phthisis bulbi from 0% to 11% have been reported after Nd:YAG CPC. 
(Trope et al. 1990, Schuman et al. 1992, Shields et al. 1994, Baez et al. 1994, Dickens et al. 1995, Zhou Wei 
et al. 1996) After 810 nm diode laser CPC, hypotonia was reported in 0% to 15% and phthisis in 0% to 2%. 
(Hawkins et al. 1993, Kosoko et al. 1996, Werner et al. 1998, Yap-Veloso et al. 1998, Youn et al. 1998, 
Spencer et al. 1999, Threlkeld et al. 1999, Walland 2000, Schlote et al. 2001b) After glaucoma implant 
surgery, 0% to 6% developed phthisis. (Lloyd et al. 1992, Noureddin et al. 1992, Lloyd et al. 1994, Krishna 
et al. 2001) 
Visual acuity decreased in 7% to 65% of eyes after Nd:YAG CPC. (Trope et al. 1990, Schuman et al. 
1992, Al-Ghamdi et al. 1993, Baez et al. 1994, Shields et al. 1994, Dickens et al. 1995, Zhou Wei et al. 1996, 
Youn et al. 1998) After 810 nm diode CPC, similarly, 18.7% to 38% lost vision (Youn et al. 1998, Yap-
Veloso et al. 1998, Spencer et al. 1999, Threlkeld et al. 1999, Mistlberger et al. 2001b) After implant 
surgery, visual deterioration occurred in 24% to 38% of patients. (Airaksinen et al. 1990, Lloyd et al. 1994, 
Välimäki et al. 1998) 
 
Posttraumatic glaucoma 
 
When needed in addition to medical therapy, filtering procedures (Mermoud et al. 1996) and glaucoma 
implant operations (Välimäki et al. 1998) are less frequently successful in patients with angle-recession 
glaucoma than in those with chronic open-angle glaucoma. Posttraumatic conjunctival and scleral 
abnormalities may even prevent incisional surgical procedures. (Mermoud et al. 1993a, Mermoud et al. 
1993b) In filtration surgery without antimetabolites, the cumulative probability of survival of the IOP was 
52% at 1 year, 32% at 3 years, and 8% at 5 years in angle-recession glaucoma in contrast to 89%, 84% and 
76% in primary open-angle glaucoma, respectively. (Mermoud et al. 1993a)  
Trabeculectomy with antimetabolites resulted in more successful cases at 3 and 6 months in angle- 
recession glaucoma than trabeculectomy without antimetabolites or Molteno implantation. (Mermoud et al. 
1993b) However, severe bleb-associated complications occurred in 15% of patients treated with 5-
fluorouracil or mitomycin C. (Mermoud et al. 1993b)  
In previously published series of cyclophotocoagulation, the proportion of eyes with posttraumatic 
glaucoma has ranged from 0% to 15%. (Hampton et al. 1990, Schuman et al. 1992, Hawkins et al. 1993, Al-
Ghamdi et al. 1993, Baez et al. 1994, Immonen et al. 1994, Shields et al. 1994, Brancato et al. 1995, Bloom 
et al. 1997, Wong et al. 1997, Kosoko et al. 1996, Zhou Wei et al. 1996, Werner et al. 1998, Spencer et al. 
1999, Therkeld et al. 1999, Schlote et al. 2001b). The published success rate in heterogeneous glaucoma 
populations after CPC has ranged from 39% to 85%. (Brancato et al. 1989, Hampton et al. 1990, Schuman et 
al. 1992, Hawkins et al. 1993, Al-Ghamdi et al. 1993, Immonen et al. 1994, Brancato et al. 1995, Bloom et 
al. 1997, Wong et al. 1997, Werner et al. 1998, Spencer et al. 1999, Therkeld et al. 1999, Schlote et al. 
2001b)  
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Table 1. Reviewed data published on transscleral cyclophotocoagulation in              
heterogeneous glaucoma populations. 
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In most studies of CPC, detailed information on the few posttraumatic patients included is limited. 
According to the available data, IOP success after CPC tends to be lower in the refractory posttraumatic 
glaucoma population than in an average glaucoma population. (Baez et al. 1994, Bloom et al. 1997, Schlote 
et al. 2001) 
 
Glaucoma in children and young adults 
 
In previously published series of CPC in young patients, Bock et al. reported a success rate of 50% in young 
patients treated with a transscleral contact 810 nm diode laser. (Bock et al. 1997) Phelan and Higginbotham 
also achieved a success rate of 50% in paediatric glaucoma patients treated with transscleral contact 
Nd:YAG laser CPC. (Phelan et al. 1995) Izgi et al. had an IOP success rate of 78% in paediatric glaucoma 
patients after 810 nm diode CPC. (Izgi et al. 2001) In a similar but larger study (n=77) published recently, 
Kirwan et al. reported IOP success in 72% 1 year and in 51% two years after 810 nm diode CPC. (Kirwan et 
al. 2001) In most previous reports on CPC, paediatric patients were not analysed separately from adult 
patients.  
Phthisis was reported in 0% (Izgi et al. 2001), 4% (Kirwan et al. 2002), and 5% (Bock et al. 1997) of eyes 
using a 810 nm contact diode laser, and in 10% (Phelan et al. 1995) of eyes using a contact Nd:YAG laser. 
Bock et al. noted a decline in vision in 18% of eyes and Phelan and Higginbotham in 40%. (Bock et al. 1997, 
Phelan et al. 1995) Izgi et al. found no VA decrease after CPC in paediatric eyes, most patients representing 
other than the refractory secondary glaucomas, as in the study by Kirwan et al., in which 8% lost vision after 
CPC. (Izgi et al. 2001, Kirwan et al. 2002)  
As shown in Table 2, the success rates obtained after CPC are in the same range as those obtained with 
other surgical treatment modalities in unselected paediatric populations.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Author Reference  n Glaucoma subtype Patient age Surgical Length of Definition of Success rate
number (years) method follow-up IOP success 
(mean, months) (mmHg)
Beauchamp et al 1979 2 22 prim. and sec. 0.8 - 20 TRE 18 < 25 50 %
Sturmer et al 1993 11 113 prim. and sec.   11 - 49 ** TRE 38  < 22 54 %
Mandal et al 1997 4 19 mainly prim.  0.7 - 18 TREcM 20  < 21 95 %
Al-Hazmi et al 1998 5 150/254* 98% prim. cong.  2 - 7 TREcM > 12  > 3, < 21 39 %
Susanna et al 1995 24 98 mainly prim. cong.  1 - 30 TREcM 15 > 4, < 22     67 %***
Beck et al 1998 25 60 mainly sec. 0.1 - 17 TREcM 30 < 22 60 %
Munoz et al 1991 26 53 inf. < 12 Molteno 18 < 22 68 %
Hill et al 1991 27 65 inf. and sec. < 21 Molteno 23 < 22 62 %
Eid et al 1997a 28 18 mainly sec. < 18 Tube-shunt > 24  > 6, < 22     44%****
Lloyd et al 1992 29    16/96* prim. and sec. < 13 Molteno 49 > 5, < 22      56%*****
    *The number of children treated versus the number of all eyes in the study.
   **No difference in treatment success according to the age of the patients.
  ***All patients, success positively correlated with increasing age.
 ****After revision operations
*****After second plate implantation
prim. = primary
sec. = secondary
cong. = congenital
inf. = infantile
TRE = trabeculectomy
TREcM = trabeculectomy with Mitomycin C
 
 
Table 2. Reviewed data published on filtration and implant glaucoma surgery in young patients. 
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Neovascular glaucoma  
 
In neovascular glaucoma, filtering procedures with or without antimetabolites, glaucoma implant operations, 
implant operations combined with pars plana vitrectomy (Sinclair et al. 1982, Mincler et al. 1988, Lloyd et 
al. 1991, Mermoud et al. 1993b, Tsai et al. 1995, Eid 1997b, Scott et al. 2000), and CPC have all been used. 
(Hampton et al. 1990, Trope et al. 1990, Schuman et al. 1992, Baez et al. 1994, Immonen 1994 et al., Seah et 
al. 1994, Shields et al. 1994, Tsai et al. 1996, Youn et al. 1996, Bloom et al. 1997, Di Staso et al. 1997, Eid 
et al. 1997b, Oguri et al. 1998, Youn et al. 1998, Yap-Veloso et al. 1998, Spencer et al. 1999, Threlkeld et al. 
1999) Filtration surgery has little chance of success unless the stimulus for new vessel formation is 
eliminated. (Wand 1996) After retinal panphotocoagulation, regression of inflammation and of iris 
neovascularization takes 3 to 4 weeks. (Wand 1996)  
In the published studies of CPC, the IOP success rates have ranged from 33% to 86% (Table 3). In most 
of these studies it was not stated whether iris neovascularization was brought to halt. Comparable success 
rates (35% to 67%) were reported in studies of filtration and implant surgery in neovascular glaucoma (Table 
4). (Allen et al. 1982, Minckler et al. 1988, Lloyd et al. 1991, Mermoud et al. 1993, Tsai et al. 1995)  
The decrease in VA after Nd:YAG CPC was shown to be high in eyes with neovascular glaucoma, partly 
as a result of hypotonia and phthisis. With the contact or non-contact Nd:YAG CPC, phthisis bulbi of up to 
19%, and visual loss of up to 56% have been reported in neovascular glaucoma (Table 3) (Hampton et al. 
1990, Trope et al. 1990, Schuman et al. 1992, Shields et al. 1994, Youn et al. 1996) VA decreased in 24% in 
a study of 810 nm diode CPC (Oguri et al. 1998). Studies on filtration and implant surgery in neovascular 
glaucoma also show a high incidence of visual decrease, of up to 62%, and of phthisis, of up to 24%. (Table 
4) (Allen et al. 1982, Minckler et al. 1988, Lloyd et al. 1991, Mermoud et al. 1993c, Tsai et al. 1995) 
 
Corneal complications after cyclophotocoagulation 
 
Several corneal complications have been described in the literature after cyclophotocoagulation with a   
Nd:YAG or a 810 nm diode laser. They include corneal burns, corneal decompensation, epithelial defects, 
bacterial ulcers, neurotrophic ulcers, band keratopathy, corneal graft failure, or an ulcer at a corneal graft. 
(Baez et al. 1994, Dickens et al. 1995, Flaxel et al. 1997, Ayyala et al. 1998, Johnson et al. 1998, Walland et 
al. 1998, Yap-Veloso et al. 1998, Jennings et al. 1999) Corneal complications are especially likely to occur 
in patients with predisposing ocular conditions, such as neovascular glaucoma in patients with diabetes or 
after central retinal vein occlusion, preoperative epithelial oedema or dystrophic calcification of the cornea, a 
corneal graft, or chronic ocular inflammation. (Flaxel et al. 1997, Ayyala et al. 1998, Johnson et al. 1998, 
Walland et al. 1998, Yap-Veloso et al. 1998) 
Corneal nutrition, surface maintenance and repair are dependent on healthy sensory innervation. 
(Beuerman et al. 1980, Beck et al. 1992)  Sensory denervation may lead to punctate neurotrophic keratitis or 
even widespread corneal epithelial detachment. (Beck et al. 1992)  In transscleral treatments in the ciliary 
region, the long posterior ciliary nerves lying in the suprachoroidal space and conducting sensory impulses 
from the cornea (Müller et al. 1997) are susceptible to damage. (Bietti 1972, Wener et al. 1973, Martin et al. 
1988) After 810 nm diode laser CPC, Johnson et al. found qualitative changes in the structure of the nerve 
fibres by transmission electron microscopy in a rabbit model: the 810 nm diode laser CPC appeared to cause 
disruption of the myelin nerve sheaths, and damaged keratocytes were also observed in the tissue samples. 
(Johnson et al. 1999) They did not find any quantitative histological changes in corneal nerve density. 
 
. 
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Table 3. Reviewed data published on transscleral cyclophotocoagulation in neovascular glaucoma. 
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Author Length of Definition of
Surgical follow-up IOP success IOP Visual decrease
 n method (mean, months) (mmHg) Success rate definition Visual decrease Phthisis
Allen et al 1988 24 filtering surgery  22.8      < 21**** 67 %         > 1 line ****** 46 % 8 %
Tsai et al 1995 34  5-FU filtering surgery    12.5** < 22 65 %  > 2 lines 53 % 24 %
Mincler et al 1988 15/79* Molteno     20.2*** < 22 47 % > 1 line 33 % 6 %
Mermoud et al 1993c 60 Molteno  24.7 < 22       35  %*****   not given 62 % 18 %
Lloyd et al 1991 10 Molteno & ppv 18.0 < 22 60 %         > 1 line ****** 60 % 0 %
IOP = intraocular pressure
5-FU = 5-fluorouracil  
ppv = pars plana vitrectomy
 
      * the proportion of neovascular glaucomatous eyes in the study
     ** median (the successful eyes)
    *** complete failures excluded
   **** plus 2 eyes in the mid-20s
  ***** eyes with loss of light perception excluded 
****** or a change in the low vision category. 
 
 
Table 4. Reviewed data published on filtration and implant surgery in neovascular glaucoma. 
 
 
Corneal morphology and corneal subbasal innervation can be evaluated in vivo with a tandem scanning 
confocal microscope (TSCM, Model 165A, Tandem Scanning Corporation, Reston, VA, USA). (Cavanagh 
et al. 1993, Linna et al. 1997) In human eyes treated with LASIK, an automated microkeratome creates a 
continuous incision and a flap in the central cornea, resulting in nerve damage, which is visible in vivo with 
the confocal microscope. Corneal nerve damage after LASIK also results in low corneal sensitivity (Linna et 
al. 2000) and a reduced rate of basic tear secretion (Yu et al. 2000) as tear fluid secretion, too, is under neural 
control. (Dartt 1994, Meneray et al. 1998)  
To the best of my knowledge, no profound studies of the possible dry eye syndrome after 
cyclophotocoagulation have been performed 
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3. Aims of the study 
 
The purpose of the present study was to evaluate the clinical applicability of long-pulsed visible red laser 
cyclophotocoagulation to the treatment of therapy-resistant glaucoma, -more specifically, 
 
 
 
 to evaluate the usefulness and complications of the 647 nm krypton red laser CPC in posttraumatic 
glaucoma, (I) 
 
to evaluate the usefulness and complications of the 647 nm krypton red laser CPC in children and young 
adults with glaucoma, (II) 
 
to evaluate the usefulness and complications of combining limited anterior retinal cryocoagulation with 
CPC performed with the 647 nm krypton or the 670 nm diode red laser in the treatment of neovascular 
glaucoma, (III) 
 
to investigate whether 670 nm diode red laser CPC has an effect on corneal morphology when studied by 
in vivo confocal microscopy, on the density of corneal subbasal nerves, on corneal mechanical sensitivity, 
and on the rate of tear fluid secretion. (IV) 
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4. Patients and Methods 
4.1. Patients  
This investigation comprised all the patients with the particular glaucoma subtypes studied who had received 
cyclophotocoagulation treatment in Helsinki University Eye Hospital (Studies I and II), all those with 
neovascular glaucoma who had received a combined CPC and limited anterior retinal cryocoagulation (Study 
III), and 10 glaucoma patients enrolled for CPC with the 670 nm diode laser (Study IV). 
The indication for cyclophotocoagulation was uncontrolled glaucoma despite maximal tolerated 
medication. The procedure was performed as an alternative to filtration or implant glaucoma surgery. Its 
purpose was to preserve vision (therapeutic treatment) or to prevent ocular pain due to high IOP in an eye 
with no visual potential (palliative treatment), as stated in the medical chart by the referring or the treating 
ophthalmologist. Of the patients who had received CPC in both eyes, one eye was chosen randomly for 
statistical analysis in all the studies.  
The indication for retinal cryocoagulation was retinal ischaemia, as demonstrated by iris 
neovascularization, and persisting after full panphotocoagulation or found to be untreatable by transpupillary 
panphotocoagulation.  
All the study protocols were reviewed by the Ethics Committee of Helsinki University Eye and Ear 
Hospital. Informed consent was obtained from all the patients in Study IV. In Studies I, II and III, follow-up 
data were gathered from the files of Helsinki University Eye Hospital, other hospitals, and private 
ophthalmologists after the signed permission of the particular patient. 
4.1.1. Transscleral Contact Krypton Laser Cyclophotocoagulation 
for Treatment of Posttraumatic Glaucoma (I)  
The criterion for inclusion was a previously performed krypton laser CPC in patients with posttraumatic 
glaucoma. The criterion for exclusion was a concurrent ocular incident, possibly affecting IOP. One patient 
was excluded from the study because of recent ocular trauma, with a giant retinal tear and detachment, and 
another patient because of a recently detected central retinal vein occlusion and neovascular glaucoma. One 
patient received a second injury to the treated eye after the one-month follow-up and his subsequent IOP data 
were excluded from the analysis. The study comprised 18 consecutive patients (7 females and 11 males) 
treated with krypton laser CPC in Helsinki University Eye Hospital from August 1991 to January 1996 for 
therapy-resistant posttraumatic glaucoma. 
The mean age of the patients at the time of the first CPC was 56.6 (range, 21 to 89) years. The types of 
the initial ocular trauma (classified according to the Birmingham eye trauma terminology system by Kuhn et 
al. (Kuhn et al. 1996)) are shown in Table 5. All patients had a therapeutic treatment indication. The first 
CPC treatment was performed 7 days to 30.5 years (mean 8.1 years) after the ocular injury. Fourteen eyes 
(77%) had undergone previous ocular procedures, which are shown in Tables 6 and 7. 
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     Type of ocular trauma Eyes % 
     Contusion injury 8 44 
     Rupture of the globe 5 28 
     Penetrating injury 4 22 
     Perforating injury 1 6 
     Total 18 100 
  
                            Table 5. Types of ocular trauma of the patients included in Study I. 
 
Glaucoma Procedures  Eyes % 
Argon laser trabeculoplasty 4 22 
670 nm diode laser CPC 1 6 
Trabeculectomy once 1 6 
Posterior sclerotomy 1 6 
Cyclocryocoagulation (twice in one eye) 1 6 
A previous glaucoma procedure performed 8 44 
  
                 Table 6. Glaucoma procedures previously performed on the patients included in Study I. 
  
Other than Glaucoma Procedures 
 
Eyes % 
Suturing of the wound after the initial trauma 10 56 
Extirpation of prolapsed uveal tissue 3 17 
Lens extraction  9 50 
IOL implantation 6 33 
Anterior vitrectomy  3 17 
Pars plana vitrectomy (three times in one eye) 4 22 
Scleral buckling (twice in one eye) 5 28 
Penetrating keratoplasty 1 6 
One or more previous procedures performed 12 67 
  
Table 7. Previous ophthalmic procedures other than glaucoma procedures performed on the 
patients included in Study I. 
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4.1.2. Transscleral Contact Krypton Laser Cyclophotocoagulation 
for Treatment of Glaucoma in Children and Young Adults (II)  
The criterion for inclusion was a previously performed krypton laser CPC in patients younger than 20 years 
of age with glaucoma. Inclusion in the study was dependent on a length of follow-up of at least one month. 
Exclusion criteria were a previously performed cyclodestructive procedure (cyclocryotherapy, four eyes, and 
670 nm diode laser CPC, one eye), and a concurrent ocular condition during follow-up possibly affecting 
IOP. One patient was excluded from the study because of recent ocular trauma, a giant retinal tear, and 
detachment, and another patient because of a fulminantly growing retinoblastoma with closed-funnel retinal 
detachment.  
The study comprised 22 patients (9 females and 13 males) under 20 years of age treated with krypton 
laser CPC in Helsinki University Eye Hospital from December 1991 to March 1998 for therapy-resistant 
glaucoma. Twenty patients had a therapeutic treatment indication whereas two patients had a palliative 
treatment indication. The mean age of the patients at the time of the first CPC was 10.5 years (range, 11 
months to 19.4 years). The glaucoma diagnoses of the patients are shown in Table 8. Sixteen eyes (73%) had 
already undergone 1 to 8 previous laser or surgical procedures, which are listed in Tables 9 and 10.     
                             
 
Glaucoma diagnosis Eyes % 
Secondary glaucoma 19 86 
- due to aphakia after congenital cataract 
extraction 
7 32 
- due to chronic uveitis 6 27 
- due to ocular trauma 2 9 
     a contusion 1 4.5 
     a penetrating injury 1 4.5 
- due to intraocular developmental abnormalities 4 18 
    Aniridia 2 9 
    Klippel-Trénaunay-Weber syndrome 1 4.5 
    Sturge-Weber syndrome 1 4.5 
Neovascular glaucoma 1 4.5 
- due to total retinal detachment  1 4.5 
Infantile glaucoma 1 4.5 
Juvenile glaucoma 1 4.5 
Total 22 100 
    
                            Table 8. Glaucoma diagnoses of the patients included in Study II. 
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Glaucoma Procedure Eyes % 
Trabeculectomy once 3 14 
Trabeculectomy twice 1 5 
Trabeculectomy three times 1 9 
Glaucoma implant operation once 2 9 
Glaucoma implant operation twice 2 9 
Glaucoma implant revision twice 1 5 
Glaucoma implant revision five times 1 5 
Liberation of pupillary adhesions 1 5 
Surgical peripheral iridectomy 1 5 
Nd:YAG laser iridotomy once 2 9 
Nd:YAG laser iridotomy twice 1 5 
A previous glaucoma procedure performed 10      45 
  
                Table 9. Glaucoma procedures previously performed on the patients included in Study II. 
 
 
Other than Glaucoma Procedures 
 
Eyes     % 
Cataract extraction with no accompanying procedures  4 18 
Cataract extraction with IOL implantation 1 4.5 
Cataract extraction with anterior vitrectomy and/or peripheral iridectomy 
and/or membranectomy 
6 27 
Discision of a secondary cataract 2 9 
Liberation of pupillary adhesions 1 4.5 
Optic iridectomy 1 4.5 
Suturation of a penetrating corneal wound 1 4.5 
A previous procedure other than glaucoma procedures performed 11 50 
 
Table 10. Previous ophthalmic procedures other than glaucoma procedures performed  
 on the patients included in Study II. 
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4.1.3. Transscleral Red Laser Cyclophotocoagulation Combined 
with Limited Anterior Retinal Cryocoagulation in Neovascular 
Glaucoma (III) 
The criterion for inclusion was a previously performed krypton or 670 nm diode laser CPC combined 
with anterior retinal cryocoagulation for neovascular glaucoma. Exclusion criteria were a previously 
performed cyclodestructive procedure (cyclocryotherapy, two patients), the use of both laser CPC modalities 
in the patient (10 patients) and a concurrent ocular condition during follow-up possibly affecting IOP. The 
study comprised 30 patients (21 females and 9 males) treated with the krypton laser (13 patients) or the 670 
nm diode laser (17 patients) CPC, followed by anterior retinal cryocoagulation for neovascular glaucoma in 
Helsinki University Eye Hospital from April 1994 to March 2000.  
The mean age of the patients at the time of the first CPC was 75.0 (range, 42 to 90) years. Three eyes had 
had chronic open-angle glaucoma, two exfoliation glaucoma, and one posttraumatic glaucoma (due to ocular 
contusion) before neovascular glaucoma was detected. Neovascular glaucoma was caused by central retinal 
vein occlusion in 23 (77%) eyes, by diabetic retinopathy in six (20%) eyes, and by occlusive disease of the 
carotid artery in one (3%) eye. Retinal photocoagulation had been commenced in four (13%) eyes and 
panphotocoagulation had been performed in seven (23%) eyes, but 19 (63%) eyes had not received any 
retinal laser ablation. Fifteen eyes (50%) had already undergone one to three laser or surgical procedures, 
which are shown in Tables 11 and 12. 
 
 
Glaucoma Procedures  Eyes % 
Nd:YAG laser iridotomy  4 13 
Argon laser trabeculoplasty once 2 7 
Argon laser trabeculoplasty twice 2 7 
Trabeculectomy  1 3 
A previous glaucoma procedure performed 7 23 
  
               Table 11. Glaucoma procedures previously performed on the patients included in Study III. 
 
Other than Glaucoma Procedures Eyes % 
Phacoemulsification and IOL implantation 7 23 
Phacoemulsification, anterior vitrectomy and IOL implantation 1 3 
Planned ECCE and anterior vitrectomy  1 3 
Retinal cryocoagulation and encirclement procedure 1 3 
Suturation of a penetrating corneal wound 1 3 
One or more previous procedures performed 10 33 
  
                Table 12 . Previous ophthalmic procedures other than glaucoma procedures  
  performed on the patients included in Study III. 
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4.1.4. Corneal Innervation, Corneal Mechanical Sensitivity, and 
Tear Fluid Secretion after Cyclophotocoagulation with the 
Transscleral Contact 670 nm Diode Laser (IV)    
The criterion for inclusion was a planned 670 nm diode laser CPC for treatment of glaucoma. Exclusion 
criteria included a cloudy cornea due to such causes as high IOP or scarring, eyes with manifest anterior 
segment disease or with a corneal graft, and also patients with diabetes, rheumatoid arthritis, amyloidosis, or 
a history of herpetic eye disease. The study comprised 10 patients (6 females and 4 males) enrolled for 670 
nm diode laser CPC in Helsinki University Eye Hospital from September 1999 to May 2000 for therapy-
resistant glaucoma. 
The mean age of the patients at the time of the first CPC was 73.8 (range, 67 to 85) years. The glaucoma 
diagnoses of the patients are shown in Table 13. Seven (70%) of the patients had undergone previous 
ophthalmic procedures, which are given in Tables 14 and 15. 
                  
                                         
Glaucoma diagnosis                                    Eyes % 
Exfoliation glaucoma 5 50 
Primary open-angle glaucoma 3 30 
Secondary glaucoma 2 20 
- due to aphakia 1 10 
- due to episcleral venous congestion 1 10 
Total 10 100 
  
                                     Table 13 . Glaucoma diagnoses of the patients included in Study IV. 
 
Glaucoma Procedure Eyes % 
Trabeculectomy  2 20 
Argon laser trabeculoplasty  5 50 
Nd:YAG laser iridotomy  1 10 
Krypton laser CPC  1 10 
A previous glaucoma procedure performed 5 50 
 
 Table 14. Glaucoma procedures previously performed on the patients included  
 in Study IV. 
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Other than Glaucoma Procedures Eyes % 
ECCE and posterior chamber lens implantation 1 10 
Phacoemulsification and posterior chamber lens implantation 1 10 
A previous procedure other than glaucoma procedures performed 2 20 
  
 Table 15. Previous ophthalmic procedures other than glaucoma procedures 
 performed on  the patients included in Study IV. 
 
4.2. Methods 
 
4.2.1. Clinical ophthalmological examination  
In Studies I, II and III, follow-up data were gathered in a retrospective chart review. Follow-up data were 
assessed within 2 weeks postoperatively and at one, 3, 6, 9 and 12 months, and thereafter every 6 months, 
after the patients´ first CPC treatment. The last follow-up available for each patient after one or more CPCs 
but no other glaucoma procedures constituted the end-point (Studies I, II, III). In the prospective Study IV, 
follow-up data were assessed within 10 days and at one month, which was the end-point in that study. 
Refraction was assessed with the lens correction achieving the best visual acuity. VA was measured using 
standard Snellen acuity charts at 5 metres. IOP was measured with the Goldmann applanation tonometer, and 
in very young patients with a SchiØtz or Tono-Pen (Mentor Inc, Norwell, MA, USA) tonometer. 
Biomicroscopy was performed with the slit lamp (Haag-Streit, Bern, Switzerland). The amount of iris 
neovascularization was assessed during biomicroscopy.  
4.2.2. Cyclophotocoagulation                                
CPC was performed under periocular anaesthesia. Ninety pecent of the CPC treatments were performed by 
Päivi Puska, MD, permanent senior ophthalmic consultant in the glaucoma service of Helsinki University 
Eye Hospital, and 10% were performed by other seniors in the research group. With the patient in the supine 
position, the ciliary body was identified by transillumination. For krypton CPC, the Lasertek 41 AKTrKr 
krypton laser unit (Dual Laser Oy, Helsinki, Finland) and, for the 670 nm diode CPC, a prototype 670 nm 
diode laser unit (Dual Laser Oy, Helsinki, Finland) was used. CPC was performed using a 1000 µm fibre and 
a contact probe with a 1200 µm ball tip (Laser Peripherals, Inc., Minnetonka, MN, USA / Dual Laser Oy, 
Helsinki, Finland), focusing the beam 2 mm in front of the probe in the air. For approximately 1 second 
before and during each application, the sclera was compressed with the probe. The power used was 0.3 to 0.5 
W with the krypton and 0.43 to 0.45 W (Scientec Calorimeter Bolden, CO, USA) with the 670 nm diode 
laser and the exposure time was 10 seconds.  
According to the general treatment protocol, the first treatment was applied to the inferior 180° of the 
ciliary body. If needed, a second treatment was given to the temporal 180°, a third treatment to the inferior 
nasal 90° and superior temporal 90°, a fourth treatment again to the inferior 180°, and a fifth treatment again 
to the temporal 180°. Thus, the superior nasal 90° of the ciliary body was left intact in an attempt to avoid 
hypotonia. In practice, the extent of the CPC was individualized according to the preoperative IOP, the 
preoperative glaucoma medication, the target pressure (therapeutic vs. palliative treatment), and the surgical 
anatomy of the eye. Approximately 10 applications were applied to the ciliary body per quadrant, avoiding 
the 9 and 3 o’clock positions. (Schuman et al. 1990)  
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In Study I, a mean number of 1.9 ± 1.2 treatments was performed per eye. Repeated CPC treatments were 
given to 44% of the eyes. A total number of 34 treatments were performed. The second CPC was performed 
a mean of  3.3 ± 2.4 (range one to 32) months since the first treatment. Two eyes (11%) received 2, 3 eyes 
(17%) 3, 2 eyes 4 (11%), and one eye (6%) 5 treatments. Of the 10 patients that were treated once, the 
treated area involved two quadrants in 8 eyes and four quadrants in 2 eyes of the ciliary body. In these 2 
eyes, the treatments covered the whole 360° of the ciliary body. Of the 8 patients that received multiple 
treatments, the total treated area involved two quadrants in one eye, three quadrants in 4 eyes and four 
quadrants in 3 eyes, covering up to 315° of the ciliary body. 
In Study II, a mean number of 2.3 ± 1.6 treatments was performed per eye. Two or more CPCs were 
given to 14 eyes (64%). The second CPC was performed after a mean interval of 5.5 ± 7.3 (range, 1 to 30) 
months since the first treatment. Eight eyes (36%) were treated once, seven eyes (32%) twice, four eyes 
(18%) 3 times, two eyes (9%) 4 times, and one eye (5%) eight times. Applications covered 90° to 360° of the 
pars plicata of the ciliary body, with approximately 10 applications per quadrant. Of a total of 50 treatments, 
four (8%) were applied to one quadrant, 32 (64%) to two quadrants, nine (18%) to three quadrants, and five 
(10%) to four quadrants of the ciliary body. Only in two eyes did the applications cover the full 360°. 
In Study III, a mean number of 1.4 ± 0.7 CPC treatments were performed per eye, and two or more CPCs 
were given to eight eyes (27%). The second CPC was performed after an interval of 2.9 ± 3.2 (range, 1 to 10) 
months since the first treatment. Five eyes (17%) were treated twice, and three eyes (10%) three times. At 
each treatment, the applications covered 90° to 270° of the pars plicata of the ciliary body. Of the total of 41 
CPC treatments, one (2%) was applied to one quadrant, 22 (54%) to two quadrants, and 17 (41%) to three 
quadrants of the ciliary body. In one case (2%) the treated area was not mentioned. Of the eight patients who 
received multiple treatments, the total treated area involved three quadrants in seven eyes and four quadrants 
in one eye, covering up to 300° of the ciliary body. Because of the higher retreatment rate in the 670 nm 
diode group (seven of 17 eyes vs. one of 13 eyes), the total area treated after all CPCs was larger in that 
group.  
To prevent a postoperative IOP rise, the patients were given one drop of 1% apraclonidine (Iopidine, 
Alcon, Fort Worth, TX, USA), and/or carbonic anhydrase inhibitors (CAI) and/or osmotic agents were 
administered pre- and postoperatively. After treatment, the patients used antibiotic -steroid drops 4 to 5 times 
a day for 3 to 4 weeks. Glaucoma medication was adjusted according to the pressure response. 
4.2.3. Limited anterior retinal cryocoagulation  
Limited anterior retinal cryocoagulation was performed once in each eye. Eighty percent of the procedures 
were performed by Docent Paula Summanen, MD, permanent senior ophthalmic consultant in the 
vitreoretinal service of Helsinki University Eye Hospital, and 20% were performed by other seniors in the 
research group. One to two rows of cryoapplications (Mira Ophthalmic Cryo CR 4000, Waltham, MA, USA) 
at -85°C and 15 to 40 in number, were applied transsclerally to 360° of the retina immediately posterior to 
the ora serrata. In 28 eyes (93%), cryocoagulation was performed under indirect ophthalmoscopic control. In  
these eyes, each application was interrupted at the earliest sign of retinal blanching. In two eyes, media 
clarity was insufficient for visual control during treatment. In these eyes, the applications were placed at a 
distance of 7 to 8 mm measured from the limbus with an application time of 5 to 7 seconds. 
Retinal cryocoagulation was performed in 22 eyes (73%) in the same session as the first CPC, in four 
eyes (13%) in the same session as a subsequent CPC, and in four eyes (13%) separately from the CPC (in 
one eye 2 months before a single CPC, 1 day after a single CPC in the second eye, 9 months after a single 
CPC in the third eye, and 2 months after a third CPC in the fourth eye). In one eye, posterior sclerotomy was 
performed during one treatment session. 
 
 
Patients and Methods 
 35 
4.2.4. Definitions of success and failure 
 
IOP success was defined as an IOP level of 8 to 21 mmHg or a decrease in IOP of more than 30% following 
one or more CPC treatments, but no other glaucoma procedures. IOP failure was defined as an IOP level of < 
8 or > 21 mmHg and a decrease in IOP of 30% or less following one or more CPC treatments, but no other 
glaucoma procedures. IOP failure was also defined to occur if the patient underwent additional glaucoma 
procedures other than a repeated CPC.  
In terms of alleviating ocular pain with CPC combined with limited anterior retinal cryocoagulation 
(Study IV), success was based on subjective assessment by the patient and was defined as the patient not 
complaining of pain during the follow-up visit, as recorded in the charts. Failure was defined as the patient 
complaining of pain during the follow-up visit, as recorded in the charts. 
4.2.5. In vivo confocal microscopy 
The central corneal morphology was examined and the subbasal innervation in the central and inferior 
perilimbal cornea was evaluated of three of the eyes without previous intraocular surgery or transscleral 
treatments with a tandem scanning confocal microscope (TSCM, Model 165A, Tandem Scanning 
Corporation, Reston, VA, USA). In vivo confocal microscopy was performed before CPC and at 3 days and 
1 month postoperatively. The confocal microscopy was performed by Docent Minna Vesaluoma, MD, of the 
cornea study group of Helsinki University Eye Hospital. Before the examination, one drop of 0.4% 
oxybuprocaine hydrochloride (Oftan Obucain®, Santen Oy, Tampere, Finland) was applied to the cornea and 
one drop of 2.5% hydroxymethylcellulose gel (Goniosol®, IOLAB Pharmaceuticals, Claremont, CA, USA) to 
the lower surface of the objective. After the examination, the gel was washed from the ocular surface, using 
artificial tears (Tears Naturale®, Alcon, Puurs, Belgium). During the examination, the patient fixated on a 
bright object with the contralateral eye to minimize eye movements. The objective lens of the microscope 
was adjusted to give an en face view of the anterior keratocytes. The setup and operation of the confocal 
microscope has been described previously. (Møller-Pedersen et al. 1997) A 24X, 0.6 NA variable working 
distance objective lens was used. With this lens, the field of view is 450 µm x 360 µm, and the z axis 
resolution is 9 µm. Images were detected using a Dage VE1000 Sit System low-light level camera (Dage-
MTI Inc., Michigan City, IN, USA) and recorded on SVHS tape (Fuji Magnetics GmbH, Kleve, Germany). 
Video images of interest were digitized, using a PC-based imaging system with custom software (University 
of Texas, Southwestern Medical Center at Dallas, TX, USA), and printed, using an Epson Stylus Color 800 
printer (Seiko Epson Corporation, Nagano, Japan).  
4.2.6. The measurement of corneal sensitivity 
The mechanical sensitivity of the four quadrants (superonasal, superotemporal, inferotemporal, and 
inferonasal) and the central cornea was tested before treatment and at 3 days and 1 month postoperatively, 
using a Cochet-Bonnet aesthesiometer (Luneau, Paris, France). The nylon monofilament had a diameter of 
0.08 mm. The patients were asked to fixate on an object 3 metres distant. Each area was tested, beginning 
with a maximal filament length of 60 mm, which was sequentially reduced by 5-mm intervals. Two to three 
positive responses to three consecutive touches were recorded as a positive result. The longest filament 
length in mm resulting in a positive response was considered to be the corneal sensitivity threshold in the 
area tested.  
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4.2.7. The measurement of the rate of tear fluid secretion  
The Schirmer basic secretion tear test (Whatman #41, CooperVision, San German, PR, USA) with topical 
anaesthesia was performed for measurement of the basic tear fluid secretion before treatment and at 1 month 
postoperatively. Five minutes after installation of oxybuprocaine hydrochloride eye drops, a Schirmer filter 
paper strip was placed in the lower temporal fornix of the eye, avoiding any irritation. The patient was then 
asked to keep both eyes gently closed for 5 minutes. The amount of wetting of the paper strip was then 
measured with a millimeter ruler.  
4.2.8. Statistical methods 
For the analyses in Studies I, II, and III, data were extracted from reviewed patient charts and statistical 
analyses were performed, using the NCSS 2000 statistical software program (NCSS Statistical Software, 
Kaysville, UT, USA). Pre- and postoperative IOP levels were compared, using the Wilcoxon signed rank 
test. Pre- and postoperative glaucoma medications were compared, using the McNemar test and the 
Wilcoxon signed rank test.  
For the analyses in Study I, The Kruskall-Wallis one-way ANOVA on ranks test was used to analyze 
differences in IOP outcome, in the duration of the treatment effect in the different glaucoma subtypes, and in 
the change in IOP according to the number of quadrants treated. The Mann-Whitney U test was used to 
analyze the extent to which the effect of the treatment depended on the patient´s age and on the total 
treatment energy. The effect of the pre- and postoperative IOPs and of the mean length of follow-up on the 
visual outcome was analyzed with the Mann-Whitney U test. The effects on visual outcome of the mean 
number of glaucoma medications, the amount of CAI used, and the number of treatments given were 
analyzed with Fisher´s exact test.  
In Study III, the Mann-Whitney U test and the Fisher´s exact test were used to analyze the differences 
between the krypton and the 670 nm diode laser treatment groups.  
For the analysis in Study IV, data were extracted completing data forms prospectively. Statistical analyses 
were performed using SPSS for Windows, ver. 7.0 (SPSS, Chicago, IL, USA). The paired samples t test was 
performed for comparison of the paired pre- and postoperative data for each individual eye.  
Differences were considered statistically significant when P < 0.05 in all analyses. Missing data were not 
substituted by any method. Only one eye of each patient was included in the statistical analyses. Statistical 
consultation was provided by Timo Pessi, M.Sc., statistician at the Department of Computer Services in 
Helsinki University Hospital. 
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5. Results 
5.1. Transscleral Cyclophotocoagulation with the Contact 
Krypton Laser for Treatment of Posttraumatic Glaucoma (I)  
5.1.1. Success of IOP 
With one or more CPCs but no other glaucoma procedures, the IOP decreased from the baseline mean  
(± SD) of 32.6 ± 12.8 to 23.6 ± 10.3 mmHg (n=17) at one month (P < 0.01), to 21.8 ± 7.5 mmHg (n=13) at 3 
months (P < 0.05), to 22.5 ± 7.6 mmHg (n=13) at 6 months (P < 0.01), and to 19.6 ± 10.5 mmHg (n=18) at 
the last control visit (3 weeks to 73 months, mean 19.4 ± 21.2 months after the first cyclophotocoagulation, P 
< 0.01). The mean IOP decreased by 40%.  
At the last control visit, the IOP success rate (an IOP of 8 to 21 mmHg or a decrease in IOP > 30%) was 
67%. All the three eyes with pretreatment IOP < 22 mmHg maintained this IOP level after treatment, but 
none achieved greater than a 30% IOP reduction. If these three eyes are classified as treatment failures, the 
success rate decreases to 50%. Surgical success rates during follow-up for various IOP criteria are given in 
Table 16. The proportions of eyes with success and failure of IOP during follow-up and the cumulative 
proportion of eyes that were lost to follow-up are shown in Figure 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Baseline <10 days 1 month 3 months 6 months last control
 Number of eyes   18 16 18 16 16 18
  < 25 mmHg  5 (28 %)  14 (88%)   9 (50%)   9 (56%)  10 (63%) 14 (78%)
  < 22 mmHg  3 (17 %)  10 (63%)   8 (44%)   8 (50%)   9 (56%) 12 (67%)
  < 17 mmHg  0 (  0 %)    6 (38%)   5 (28 %)   3 (19%)    2 (13%)   7 (39%)
  > 30 % decrease in IOP  10 (63%)   7 (39%)   8 (50%)    6 (38%)   8 (44%)
  > 30 % decrease in IOP or IOP < 22 mmHg  13 (81%) 10 (56%) 10 (63%)  10 (63%) 12 (67%)
6-24 mmHg  5 (28 %)  14 (88%)   9 (50%)   9 (56%)  10 (63%) 13 (72%)
6-21 mmHg  3 (17 %)  10 (63%)   8 (44%)   8 (50%)   9 (56%) 11 (61%)
8-21 mmHg  3 (17 %)  10 (63%)   7 (39%)   8 (50%)   9 (56%) 10 (56%)
8-16 mmHg  0 (  0 %)    6 (38%)   4 (22%)   3 (19%)   2 (13%)   5 (28 %)
Eyes treated with other glaucoma procedures after CPC were considered to be failures. Two patients had missing IOP values at 10 days 
and one patient at 3 months. One patient got a second injury to the treated eye after the one month follow-up and his subsequent 
IOP data were excluded from the analysis. Another patient died 4 months postoperatively.
Last follow up = The last check-up visit for which intraocular pressure data are available (mean, 19.4 ± 21.2 months after the initial 
cyclophotocoagulation). For eyes that received other additional glaucoma procedures, the last available intraocular pressure 
before such an operation was used. 
 
Table 16. Surgical success rates with different IOP criteria during follow-up after one or more krypton 
cyclophotocoagulations but no other glaucoma procedures. 
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Figure 4. The proportions of eyes with success and failure of IOP during follow-up in Study I. The 
cumulative proportions of eyes with success and failure of IOP that were no longer in follow-up at the time 
point in question are also shown. 
Definition of success of IOP: an IOP level of 8 to 21 mmHg or a decrease in IOP of > 30% from the 
baseline. Instead of missing values, the previous value observed in a particular patient was carried  forward.  
 
Other glaucoma procedures than a repeated CPC were performed on 4 patients. One eye was treated with 
trabeculectomy at one month, one with cyclocryocoagulation at one month, and 2 with glaucoma implant 
surgery: one at 3 weeks and the other at 15 months after the first CPC. IOP and other data measured after 
additional glaucoma procedures were excluded from the analysis. During follow-up, phacoemulsification 
with IOL implantation was performed in one eye at 5 months and intracapsular cataract extraction (ICCE) 
and anterior vitrectomy with IOL implantation at 18 months in one eye.  
5.1.2. Glaucoma medication 
At baseline (n=18), 17 patients (94%) had glaucoma medication, and 12 (67%) received peroral CAI in 
addition to topical treatment. At the last control visit, 15 of the 18 patients (83%) had glaucoma medication 
after one or more CPCs, and 7 (39%) used peroral CAI with topical medication. The median number of 
topical glaucoma medications was 2 preoperatively and 1 at the last control visit. The median daily dose of 
CAI was 250 mg preoperatively and 0 mg at the last control visit. The reduction in glaucoma medication 
during the follow-up did not reach statistical significance. 
5.1.3. Visual acuity 
An increase in VA of more than 2 Snellen lines or a change in low vision category was found in 4 
patients (22%). The reason for this was the correction of a refractive error in one patient, visual recovery 
after the initial trauma in 2 patients and phacoemulsification with IOL implantation at 5 months in one 
patient, in whom VA had been within one Snellen line during follow-up before the cataract operation. 
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A decline in VA of more than 2 Snellen lines or a change in low vision category occurred in 3 eyes 
during the follow-up period. The decline in VA was due to punctate corneal epitheliopathy at the last control 
visit of one patient with no such findings at previous visits, to a dry corneal epithelium in the second eye 
with fluctuation of vision, and the development of phthisis in the third eye. In 2 of these eyes, the decline in 
VA was considered to be potentially CPC-related.  
5.1.4. Complications 
Postoperative complications, their frequencies and whether or not they were transient are shown in Table 17. 
No conjunctival burns or fibrinoid reactions were seen, nor did the patients report significant postoperative 
pain requiring systemic analgesics. Corneal punctate epitheliopathy or dry eye was seen after 2 treatments 
(6%). After the third treatment of one eye, the cornea appeared permanently dry. One eye with silicone oil in 
the anterior chamber developed corneal opacification after delayed healing of a corneal epithelial defect one 
month after CPC and mild anterior chamber irritation chronically thereafter. One eye showed small patches 
of scleral thinning in the treatment area after the third CPC. 
One patient had macular oedema at the first examination after a contusion injury. It disappeared within a 
week, but developed again 5 days after CPC (21 days after the initial trauma). The oedema resolved again 
completely and the patient gained 20/20 vision during follow-up.  
Hypotonia (IOP < 6 mmHg) was seen in one eye with perforating injury and four subsequent posterior 
segment operations with silicone oil injection. An IOP of 6 mmHg was first measured at one month 
postoperatively (the CPC covered 360° of the ciliary body), but when the glaucoma medication was reduced, 
the IOP returned to normal in this patient within 3 months after CPC. However, 2 years postoperatively, 
hypotonia (IOP of 5 to 7 mmHg) again developed without glaucoma medication. At the last follow-up at 5 
years and 3 months postoperatively, the IOP in this patient was 6 mmHg.  
Hypotonia and phthisis developed in another eye with a contusion injury, lens subluxation and vitreous 
prolapse into the anterior chamber. This eye had received 3 CPCs covering 315° of the ciliary body within 7 
months, the first treatment 2 days after the initial injury. An IOP of one mmHg developed one month after 
the last CPC. After 4 months of hypotonia, the IOP returned to 6 mmHg and after 7 months to 12 mmHg. 
Four months later (11 months after the last CPC) ICCE, anterior vitrectomy and anterior chamber lens 
implantation were performed. Before the cataract operation, the IOP had been 22 mmHg without glaucoma 
medication. Five months after cataract surgery, hypotonia (an IOP of one mmHg) again developed and 
phthisis bulbi followed 2 years and 2 months after the last CPC.  
 
Complication * 
Transient 
Treatments 
 (%) 
Dry eye or corneal punctate epitheliopathy    2  (6) 
Corneal epithelial erosion and subsequent opacification    1  (3) 
Corneal marginal ulcer *   1  (3) 
   
Mild anterior uveitis * 13 (38) 
   
Macular oedema (previously posttraumatic oedema) *   1  (3) 
Mild scleral thinning    1  (3) 
Hypotonia (IOP < 6 mmHg) *   1  (3) 
   
Complication * Transient Eyes (%) 
Phthisis bulbi    1  (6) 
 
Table 17. Complications after 34 cyclophotocoagulation treatments with the krypton  
 laser in 18 eyes of 18 patients with posttraumatic glaucoma. See text for a   
 more detailed descriptions of some patients. 
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5.2. Transscleral Cyclophotocoagulation with the Contact 
Krypton Laser for Treatment of Glaucoma in Children and Young 
Adults (II)  
5.2.1. Success of IOP 
Preoperatively, the mean IOP was 35.0 ± 7.9 mmHg (n=22). After one or more CPCs, the mean IOP 
decreased to 21.5 ± 8.7 mmHg (n=22) at 1 month (P < 0.001), to 23.4 ± 8.6 mmHg (n=18) at 3 months (P < 
0.001), to 25.0 ± 12.1 mmHg (n=19) at 6 months (P < 0.01), to 22.1 ± 9.1 mmHg (n=16) at 1 year (P < 0.01), 
to 22.6 ± 10.3 (n=11) at 2 years (P < 0.01), and to 26.2 ± 10.5 mmHg (n=22) at the last follow-up visit (1 to 
74 months, mean 27.1 ± 21.9 months after one or more CPCs but no other glaucoma procedures, P < 0.01).  
At the last control visit, the IOP success rate (an IOP of 8 to 21 mmHg or a decrease in IOP > 30%) was 
64%. Surgical success rates during follow-up for various IOP criteria are given in Table 18. The proportions 
of eyes with IOP success and failure during follow-up and the cumulative proportions of eyes that were lost 
to follow-up are shown in Figure 5.  
The total number of quadrants of the ciliary body treated did not correlate statistically with the IOP 
results. The difference in IOP outcome or in the means of the follow-up time after one or more CPCs in eyes 
with congenital glaucoma (n=7), eyes with uveitic glaucoma (n=6) and the other eyes with various other 
glaucoma diagnoses (n=9) was not statistically significant.  
The mean duration of the treatment effect (IOP < 22 mmHg or IOP reduction > 30%) of all patients´ first 
CPC was 6.8 ± 10.5 months (median 2.0 months, range, no effect to 35 months). None of the three 
diagnostic groups had longer or shorter treatment effects than any other. The longest treatment effects were 
shown by two uveitic eyes (31 to 35 months), one post-traumatic glaucomatous eye (24 months) and one eye 
operated on for congenital cataract (20 months). Within the follow-up period, five of the 22 eyes still showed 
a treatment effect after only one CPC (two uveitic eyes, one eye with juvenile glaucoma, one post-traumatic 
glaucomatous eye, and one eye operated on for congenital cataract). Nor was there a statistically significant 
difference in the treatment effect between patients treated with a higher- and with a lower-than-median 
amount of energy (70 J, range, 44 to 113 J). There was no statistically significant difference in the mean 
duration of the treatment effect between 11 patients older than and 11 patients younger than the median age 
of 10 years. 
Additional glaucoma procedures were performed on nine eyes (see Table 19). For eyes that received other 
additional glaucoma procedures, the last available IOP before such an operation was used in the calculations.  
During follow-up, Nd:YAG laser capsulotomy was performed in one patient at 7 months and cataract 
extraction was performed in another patient at 2 years.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Baseline 1 month 3 months 6 months 1 year 2 years last follow-up
Number of eyes* n=22 n=22 n=19 n=21 n=20 n=18 n=22
IOP criterion
< 25 mmHg 1(4%) 16(73%) 10(53%) 11(52%) 10(50%) 8(44%) 9(41%)
< 22 mmHg 0(0%) 13(59%) 7(37%) 8(38%) 8(40%)  7(39%) 9(41%)
6-21 mmHg 0(0%) 12(55%) 6(32%) 8(38%) 8(40%)  7(39%) 9(41%)
8-21 mmHg 0(0%) 12(55%) 6(32%) 7(33%) 8(40%)  7(39%) 9(41%)
6-24 mmHg 1(4%) 15(68%) 9(47%) 11(52%) 10(50%) 8(44%) 9(41%)
8-24 mmHg 1(4%) 15(68%) 9(47%) 10(48%) 10(50%) 8(44%) 9(41%)
>30% decrease in IOP 16(73%) 10(53%) 13(62%) 9(45%) 9(50%) 13(59%)
>30% decrease in IOP or IOP< 22 mmHg 16(73%) 10(53%) 13(62%) 9(45%) 9(50%) 14(64%)
*The total number of eyes at each time point gives the number of eyes deemed as successes at the given time point plus the number of patients
regarded as failures at the given time point or at any previous time point. The number excludes eyes lost to follow-up  
(one eye after 1 month with an IOP of 16 mmHg, and three additional eyes after 1 year with last recorded IOPs of 10, 16 and 25 mmHg). 
The IOP data of two patients were missing at 3 months and that of one patient was missing at 1 year.
Last follow up = The last check-up visit for which IOP data are available (mean, 27.1 ±  21.9 months after the initial CPC).
Of eyes that received other additional glaucoma procedures, the last available IOP before such an operation was used.  
Table 18. Number and proportion of eyes on a specific intraocular pressure (IOP) level during follow-up 
after one or more cyclophotocoagulations (CPC) but no other glaucoma procedures. 
Results 
 41 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. The proportions of eyes with success and failure of IOP during follow-up in Study II. The 
cumulative proportions of eyes with success and failure of IOP that were no longer in follow-up at the time 
point in question are also shown.  
Definition of success of IOP: an IOP level of 8 to 21 mmHg or a decrease in IOP of > 30% from the 
baseline. Instead of missing values, the previous value observed in a particular patient was carried  forward.  
 
  
Procedure Eyes   (%) Time after the initial CPC 
(months) 
Trabeculectomy 2       (9%) 3 and 8 
Implant surgery 4     (18%) 4, 11, 13, and 33 
Nd:YAG laser iridotomy 2       (9%) 8 and 20 
670 nm diode laser CPC 1       (5%) 62 
  
  Table 19. Additional procedures performed for glaucoma during follow-up after one  
  or more CPCs in the eyes in Study II. 
5.2.2. Glaucoma medication 
 
At baseline (n=22), 20 eyes (91%) had glaucoma medication, and four patients (18%) received peroral CAI 
in addition to topical treatment. At the last follow-up visit, after one or more CPCs but no other glaucoma 
procedures, 17 eyes (77%) were on glaucoma medication (P < 0.05) and four patients (18%) were using 
peroral CAI. The median number of topical glaucoma medications pre- and postoperatively was 2.  
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5.2.3. Visual acuity 
An increase in VA of more than two Snellen lines or a change in the low vision category was found in one 
patient (5%) after correction of refractive error, and in another patient (5%) after visual recovery from ocular 
trauma.  
A decline in VA of more than two Snellen lines or a change in the low vision category occurred in four 
(18%) of the 22 eyes. The reason for this was progression of pre-existing lens opacification and band 
keratopathy (one eye), progression of a pre-existing cyclitic membrane (one eye), postoperative exacerbation 
of chronic uveitis (one eye), and progression of pre-existing, posttraumatic corneal decompensation and 
uveitis (in one eye). In five patients, the change in VA could not be evaluated because of lack of co-
operation. 
Nd:YAG laser capsulotomy was performed in one patient at 7 months and cataract extraction was 
performed in another patient at 2 years. Before these procedures, VA had been within one Snellen line during 
follow-up in both eyes. 
 
5.2.4. Complications 
 
Postoperative complications and events, their frequencies and whether they were transient are given in Table 
20. No conjunctival burns were seen. Ten (20%) cases of corneal punctate epitheliopathy or dry cornea were 
transiently noted (four within 2 weeks, one at 1 month and five at 3 to 5 months). Band keratopathy 
progressed in three (14%) eyes: in two aniridic eyes with progressive corneal subepithelial and stromal 
degeneration before the CPC, and in one uveitic eye. Subtle transient (4 to 5 months) subepithelial corneal 
opacification or infiltration developed in one epikeratophacic eye and in one uveitic eye. Mild limbal vessel 
growth with no progression was seen at 1 month in an eye after four previous intraocular operations. Scleral 
thinning developed in the treatment area in two patients: after a single treatment in one eye of a 13-year-old 
patient with uveitic glaucoma and after each of two treatments in one eye of an 11-year-old patient operated 
on for congenital cataract. 
After one CPC treatment (2%), transient hypotonia (an IOP of 3 to 6 mmHg) was seen for 6 months in an 
eye with a preoperative cyclitic membrane. The eye had previously been operated on for congenital cataract 
and secondary glaucoma (two implant operations). A shallow anterior chamber developed 5 to 6 months 
postoperatively in two eyes with preoperative uveitis and cyclitic membranes. No cases of phthisis bulbi 
were seen.  
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Complication *  
Transient 
Treatments  
(%) 
Dry eye or corneal punctate epitheliopathy * 10 (20) 
Subtle subepithelial corneal opacification or infiltrates  *   2   (4) 
Mild limbal vessel growth     1   (2) 
   
Marked ciliary injection (uveitic eyes) *   2   (4) 
Minor anterior uveitis *   8 (16) 
Moderate anterior uveitis (uveitic eyes) *   2   (4) 
Shallow anterior chamber    2   (4) 
Fibrinoid reaction (preoperative hyphema in one eye) *   2   (4) 
Oval pupil *   1   (2) 
   
Minor anterior vitritis  *   3   (6) 
Scleral thinning    3   (6) 
   
Hypotonia (IOP 3 to 6 mmHg)  *   1   (2) 
Disturbance of near vision  *   1   (2) 
Postoperative pain  *        2   (4) 
 
Complication *  
Transient 
  Eyes            
(%) 
Progression of band keratopathy       3  (14) 
Progression of a pre-existing subcapsular cataract       4  (18) 
  
 
 Table 20. Complications after 50 cyclophotocoagulation treatments with the krypton  
 laser in 22 eyes of 22 children and young adults. See text for more detailed descriptions  
 of some patients.  
 
 
5.3. Transscleral Cyclophotocoagulation with the Red Laser 
Combined with Limited Anterior Retinal Cryocoagulation in 
Neovascular Glaucoma (III).  
There were no statistically significant differences between the krypton and the 670 nm diode groups in the 
patients´ age, sex, glaucoma medication, extent of retinal photocoagulation pre- or postoperatively, 
perioperative additional glaucoma medication, amount of total energy used in the first CPC (72.5 ± 11.7 
(range, 57.0 to 96.2) J and 80.4 ± 21.8 (range, 38.7 to 116.1) J, respectively) or extent of the area treated in 
the first CPC. Because of the higher retreatment rate in the 670 nm diode group where 7 eyes (41%) were 
retreated compared with one retreated eye (8%) in the krypton group, the total area treated after all CPCs was 
larger and the total amount of energy delivered per eye was higher in the 670 nm diode laser group (P < 
0.05). 
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5.3.1. Success of IOP 
With one or more CPCs and an anterior retinal cryocoagulation, the mean IOP decreased from a preoperative 
level of 44.0 ± 12.5 (range, 22 to 70) mmHg (n=30) to 22.1 ± 15.8 (range, 0 to 72) mmHg (n=30) at the last 
follow-up, which was at a mean of 16.8 ± 13.8 months (median 11.5, range, 1 to 45 months) after the initial 
CPC (P < 0.0001). In the krypton and 670 nm diode groups, the mean IOPs at baseline were 45.1 ± 12.2 
(range, 25 to 64) and 43.1 ± 13.1 (range, 22 to 70), respectively, decreasing to 23.6 ± 16.6 (range, 5 to 72), 
and 20.9 ± 15.6 (range, 0 to 58). The last control visit took place at a mean of 21.3 ± 14.4 (range, 4 to 43) 
months after the initial CPC in the krypton group, and 13.1 ± 12.7 (range, 1 to 45) months after the initial 
CPC in the 670 nm diode group. These differences between the two groups were not statistically significant.  
In the patients with a therapeutic treatment indication (n=19), the IOP decreased from a preoperative 
mean level of 40.9 ± 11.8 (range, 22 to 62) mmHg to 15.6 ± 5.9 (range, 5 to 26) mmHg (n=19) (P < 0.001) at 
the last follow-up, which was a mean of 14.0 ± 12.2 (range, 1 to 43) months after the first CPC. At the last 
control visit in these 19 patients, the IOP success rate (an IOP of 8 to 21 mmHg or a decrease in IOP > 30%) 
was 95%. The IOP success rates of these 19 patients during follow-up, using various IOP criteria, are given 
in Table 21, and the proportions of these eyes with IOP success and failure during follow-up and the 
cumulative proportions of eyes that were lost to follow-up are shown in Figure 6. At the last follow-up, all 
the patients (n=30) were pain-free.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Baseline < 10 days 1 month 3 months 6 months 1 year last follow-up
Number of eyes* n=19 n=19 n=18 n=14 n=11 n=9 n=19
                 IOP criterion
< 25 mmHg   2 (11%) 14 (74%) 13 (72%) 14 (100%) 9 (82%) 8   (89%) 17 (89%)
< 22 mmHg   0   (0%) 11 (58%) 12 (67%) 13   (93%) 9 (82%) 8   (89%) 17 (89%)
5-21 mmHg   0   (0%) 10 (53%) 10 (56%) 13   (93%) 9 (82%) 8   (89%) 17 (89%)
8-21 mmHg   0   (0%) 10 (53%) 10 (56%) 12   (86%) 8 (73%) 8   (89%) 15 (79%)
5-24 mmHg   2 (11%) 13 (68%) 11 (61%) 14 (100%) 9 (82%) 8   (89%) 17 (89%)
8-24 mmHg   2 (11%) 13 (68%) 11 (61%) 13   (93%) 8 (73%) 8   (89%) 15 (79%)
> 30% decrease in IOP 14 (74%) 13 (72%) 11   (79%) 7 (64%) 9 (100%) 17 (89%)
> 30% decrease in IOP or IOP < 22 mmHg 15 (79%) 14 (78%) 14 (100%) 9 (82%) 9 (100%) 18 (95%)
> 30% decrease in IOP or IOP 8 to 21 mmHg 15 (79%) 14 (78%) 14 (100%) 9 (82%) 9 (100%) 18 (95%)
   
*The total number of eyes at each time point gives the number of eyes deemed as successes at the given time point plus the number of eyes
regarded as failures at the given time point, or at any previous time point. The number excludes eyes lost to follow-up  
(two eyes after 1 month with an IOP of 17 and 20 mmHg, 3 eyes after 3 months (5, 12, and 14 mmHg), 
and five eyes after 6 months (5, 10, 17, 18, and 20 mmHg). The IOP data of one patient at 1 month, of three patients at 3 months, 
and of three patients at 6 months, were missing.
Last follow up = The last check-up visit for which intraocular pressure data are available (mean, 14.0 ± 12.2 months after the initial 
cyclophotocoagulation). For eyes that received other additional glaucoma procedures, the last available intraocular pressure before 
such an operation was used. 
 
 
Table 21. Number and proportion of eyes in the therapeutic group on a specific intraocular pressure (IOP) 
level during follow-up after one or more cyclophotocoagulations (CPC) but no other glaucoma procedures. 
 
 
Glaucoma procedures other than repeated CPC treatments, were not performed during the follow-up. 
Phacoemulsification and IOL implantation were performed in one eye at 2 months, Nd:YAG laser 
capsulotomy in one eye at 12 months, and pars plana vitrectomy and silicone oil injection for traction retinal 
detachment in one eye at 9 months after the first CPC. By the last follow-up, 15 eyes (50%) had received 
retinal panphotocoagulation. 
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Figure 6. The proportions of eyes with IOP success and failure during follow-up (n=19, patients with a 
therapeutic treatment indication) in Study III. The cumulative proportions of eyes with success and failure of 
IOP that were no longer in follow-up at the time point in question are also shown. 
Definition of success of IOP: an IOP level of 8 to 21 mmHg or a decrease in IOP of > 30% from the 
baseline. Instead of missing values, the previous value observed in a particular patient was carried  forward.  
5.3.2. Glaucoma medication 
At baseline (n=30), 26 (87%) patients were on glaucoma medication. Eighteen (60%) patients took topical 
glaucoma medication only, and eight (27%) were taking systemic CAI with topical treatment. At the last 
follow-up visit (n=30), after one or more CPCs but no other glaucoma procedures, 20 (67%) patients were on 
glaucoma medication. Of these, one patient (3%), as compared with eight (27%) at baseline, was using 
peroral CAI (P < 0.05). Preoperatively, the median number of topical glaucoma medications was 2, and 
postoperatively 1 (P < 0.05). 
5.3.3. Regression of iris neovascularization and resolution of 
vitreous haemorrhage 
In 13 (43%) cases, iris neovascularization regressed or disappeared during follow-up. All three eyes with 
preoperative vitreous haemorrhage preventing retinal photocoagulation showed resolution of the 
haemorrhage, enabling fundus examination at or before the last follow-up. 
5.3.4. Visual acuity 
In four (21%) of the 19 eyes of the patients with an indication for therapeutic treatment, an increase in VA of 
more than two Snellen lines or a change in the low vision category was found: after the IOP had decreased 
and corneal epithelial oedema had resolved (three eyes), and after Nd:YAG laser capsulotomy (one eye). 
Before capsulotomy, VA had been within one Snellen line during follow-up. 
In 15 (50%) of all eyes and in eight (42%) of the 19 eyes of the patients with an indication for therapeutic 
treatment, a decline in VA of more than two Snellen lines or a change in the low v ision category occurred. In 
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the patients with an indication for palliative treatment, the reason for the visual decline was high IOP and 
progression of the coexisting retinal disease. In those with an indication for therapeutic treatment, the reason 
was progression of the retinal disease (five eyes), progression of a pre-existing lens opacification (two eyes), 
and vitreous haemorrhage and intermittent poor control of glaucoma despite an IOP within the normal range 
at the last follow-up (one eye).  
One patient was operated on for cataract at 2 months, but VA deteriorated owing to the progression of the 
coexisting retinal disease. Before cataract operation, VA had been within one Snellen line during follow-up. 
5.3.5. Complications 
Postoperative complications, their frequencies and whether they were transient are given in Table 22. The 
two laser treatment groups did not differ significantly in the number or severity of the complications noted.  
No conjunctival burns were seen. Of the four cases (9%) of dry eye, three were transient. One was seen at 
3 days and three were seen during the first 3 months. One of these eyes, with no light perception (palliative 
treatment), had a persistently elevated IOP and corneal epitheliopathy. The patient requested enucleation, 
which was performed 8 months postoperatively.  
  
 
Complication *  
Transient 
Treatments  
(%) 
Postoperative pain *   3    (7) 
Lid oedema *   1    (2) 
Sugillation *   3    (7) 
Ciliary injection *   8  (18) 
Chemosis * 19  (42) 
Dry eye *   4    (9) 
Corneal dellen *   1    (2) 
Corneal epithelial erosion *   1    (2) 
Corneal epithelial erosion and subsequent haze, 
precipitates, and prolonged anterior uveitis  
   1    (2) 
Corneal epithelial oedema *   1    (2) 
Folding of Descemet´s membrane *   1    (2) 
   
Mild anterior uveitis * 18  (40) 
Fibrinoid reaction  *   3    (7) 
Hyphaema *   3    (7) 
 
Complication *  
Transient 
Eyes              
(%) 
Progression of a pre-existing cataract    2    (7) 
Late vitreous haemorrhage (at 2 to 33 months)    5  (17) 
Traction retinal detachment    1    (3) 
Hypotonia (IOP of 5 mmHg)    1    (3) 
Phthisis bulbi    1    (3) 
 
Table 22. Complications after a total of 45 treatment sessions in 30 eyes 
of 30 patients with neovascular glaucoma in Study III. See text for more detailed   
descriptions of some patients.  
 
 
Results 
 47 
Anterior chamber haemorrhage was seen after three treatments (7%): in one eye with previous 
spontaneous anterior chamber haemorrhages, and in another eye peroperatively following posterior 
sclerotomy (hypotonia caused bleeding from neovascular vessels of the iris). The third case only occurred 1 
month postoperatively. Three (7%) fibrinoid reactions were seen, two in eyes with an anterior chamber 
haemorrhage, and in one eye 3 months after treatment.  
One eye (3%) had an IOP of 5 mmHg without glaucoma medication at the last follow-up (at 3 months). 
The only case of phthisis developed gradually during 39 months. During follow-up, one eye (3%) with 
proliferative diabetic retinopathy was operated on at 9 months for traction retinal detachment. 
 
 
5.4. Corneal Innervation, Corneal Mechanical Sensitivity, and 
Tear Fluid Secretion after Transscleral Cyclophotocoagulation 
with the Contact 670 nm Diode Laser (IV)    
5.4.1. Morphology of the central cornea  
In the central corneas, the outer and basal epithelial cells were normal in shape and reflectivity at all 
examinations. (Li et al. 1997, Møller-Pedersen et al. 1997, Rosenberg et al. 2000a, Vesaluoma et al. 2000) 
The anterior keratocyte nuclei were clearly discernible in all the corneas, although in two of them the 
anterior matrix was less transparent than in healthy eyes of young individuals (Original Article IV, Figure 
2A). Keratocyte activation, described as brightly reflecting keratocyte nuclei and visible cell processes, 
(Møller-Pedersen et al. 1997, Vesaluoma et al. 2000) was not observed after the treatment. In all cases 
following the 670 nm diode laser CPC, the posterior stroma appeared normal, and did not reveal any changes 
in morphology. The endothelial cells were regularly distributed and appeared hexagonal in shape. 
5.4.2. The subbasal nerves of the central cornea  
In the pretreatment images, the central corneal nerve fibre bundles forming the subbasal nerve plexus 
appeared less abundant than in normal young individuals (Original Article IV, Figure 2B). (Rosenberg et al. 
2000b) In the best images with most nerve fibre bundles, the central corneas of the patients exhibited only 
one to three long nerve fibre bundles. Their course was not normal, as short nerve fibre bundles, not found in 
the normal subbasal corneal innervation, were also occasionally observed, and some of the long nerves were 
not straight (Original Article IV, Figure 2C). However, the nerve counts had not decreased during the follow-
up; in fact, in one case, more bundles were observed at 1 month than at earlier time points (Original Article 
IV, Figures 2B-D). No particular changes in the morphology or density of the nerve fibre bundles were 
detected during the follow-up. Images of central stromal nerve trunks could be visualized at all examinations 
and appeared normal (Original Article IV, Figure 2E).  
5.4.3. The subbasal nerves of the inferior perilimbus 
In the inferior perilimbal area, both long and short subbasal nerve fibre bundles were observed, but, in this 
area also, the images remained unchanged at all time points. In one cornea, small, round, highly reflecting 
cells, presumably of inflammatory origin, were connected to the short nerve fibre bundles at all examinations 
(Original Article IV, Figure 2 F). 
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5.4.4. Corneal sensitivity 
Comparison of the pre- and postoperative data for each corneal area in each individual eye showed that there 
was no statistically significant change in the mechanical sensitivity values in any of the corneal areas 
examined (P > 0.05).  (Table 23).  
 
 
 Baseline (n = 10) 3 days (n = 9) one month (n = 9) 
    
Superonasal 54.5 ± 8.3 (40.0 to 60.0) 56.7 ± 6.6 (40.0 to 60.0) 55.0 ± 5.0 (45.0 to 60.0)  
 
 (n.s.) (n.s.) 
 
   
Superotemporal  56.5 ± 5.8 (45.0 to 60.0)  57.2 ± 3.6 (50.0 to 60.0)  58.3 ± 2.5 (55.0 to 60.0) 
 
 (n.s.) (n.s.) 
 
   
Inferotemporal 58.0 ± 6.3 (40.0 to 60.0) 58.9 ± 2.2 (55.0 to 60.0) 57.8 ± 3.6 (50.0 to 60.0)  
 
 (n.s.) (n.s.) 
 
   
Inferonasal  55.5 ± 8.3 (35.0 to 60.0)  57.2 ± 6.7 (40.0 to 60.0) 57.8 ± 3.6 (50.0 to 60.0)  
 
 (n.s.) (n.s.) 
 
   
Central  55.5 ± 8.3 (35.0 to 60.0)  57.2 ± 3.6 (50.0 to 60.0)  57.2 ± 5.7 (45.0 to 60.0)  
  (n.s.) (n.s.) 
  
Table 23. The mean ± SD (range) mechanical sensitivity of the central cornea and its four quadrants  
of ten glaucomatous eyes preoperatively and after 670 nm diode laser cyclophotocoagulation. 
5.4.5. Tear fluid secretion 
On comparing the pre- and postoperative data for each individual eye, there was no statistically significant 
change in the results of the Schirmer basic secretion tear test (P > 0.05) (Table 24). Before treatment, the 
eyes were classified into three categories according to the test readings (Fingeret et al. 1990): those with 
normal values (> 10 mm), those with borderline values (5 to 10 mm), and those with pathological values (< 5 
mm). One month after treatment, three eyes showed no change in category, four eyes showed a change to a 
lower category and two showed a change to a higher category.  
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Patient Results of the Schirmer basic secretion tear test                    
(the amount of wetting of the filter paper strip in mm) 
 
 
Baseline 1 month   Change in category 
1 3 9 Higher 
2 5 2 Lower 
3 5 22 Higher 
4 14 9 Lower 
5 33 24 No change 
6 12 4 Lower 
7 2 0 No change 
8 6 9 No change 
9 18 n.d.  
10 12 6 Lower 
Mean 11.0 9.4  
SD 9.6 8.3  
 
 
                                    Table 24. Results of the Schirmer basic secretion tear test at baseline and  
                                    at 1 month after 670 nm diode laser cyclophotocoagulation. 
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6. Discussion 
6.1. Cyclophotocoagulation 
Cyclophotocoagulation has been widely used in therapy-resistant glaucoma. (Schuman et al. 1990a) In an 
Ophthalmic Technology Assessment (OTA) by the American Academy of Ophthalmology (AAO) (Pastor et 
al. 2001) based on the current literature, it was found that cyclophotocoagulation (based on Level III 
evidence) is indicated for patients with refractory glaucoma in whom trabeculectomy or tube shunt 
procedures have failed, patients with minimal useful vision and elevated IOP, patients who have no visual 
potential and need pain relief, and patients with complicated glaucoma and conjunctival scarring from 
previous surgery. It may be useful for patients whose general medical condition precludes invasive surgery 
(i.e. filter or tube) and is useful in emergency situations, such as the acute onset of neovascular glaucoma. 
(Pastor et al. 2001) 
6.1.1. Methodological considerations and qualities of the laser 
In this study, we placed the laser probe on the anterior edge of the illuminated ciliary body and held it 
perpendicular to the sclera. This individualized technique has been shown to destroy the ciliary ridges 
optimally (Bloom et al. 1992, Kivelä et al. 1995) Two reports of treatment failures after contact 810 nm 
diode CPC performed with the G-probe placed at the limbus revealed lesions situated more posteriorly than 
intended in the pars plana. (Walland et al. 1998, Barkana et al. 2002) Walland et al. studied autopsy eyes and 
concluded that the lack of flexibility of the standard G-probe suggested that, in eyes at the extremes of size, 
an individualized technique should be considered instead. (Walland et al. 1998) Barkana et al. viewed                    
the ciliary body as they performed endoscopic CPC after three transscleral CPC treatments. Scleral 
transillumination had only been applied in the repeat treatments. The authors concluded that scleral 
transillumination did not correctly reflect the anatomy of the elongated ciliary processes since many laser-
induced scars were noted in the pars plana. However, it is not known which of the burns were performed 
with the assistance of transillumination and which without it.   
The choice of the laser type has been based on the scleral transmission of the laser used. Since scleral 
transmission increases at longer wavelengths, (Vogel et al. 1991) the lasers most frequently employed in 
clinical practice have been the infrared 810 nm diode and the 1064 nm Nd:YAG lasers. (Hampton et al. 
1990, Schuman et al. 1992, Shields et al. 1994, Dickens et al. 1995, Kosoko et al. 1996, Bloom at al 1997, 
Werner et al. 1998, Yap-Veloso et al. 1998, Spencer et al. 1999, Threlkeld et al. 1999, Schlote et al. 2001b, 
Mistlberger et al. 2001)  
When a transscleral contact laser application is used while simultaneously compressing the sclera with the 
probe, the scleral transmission is increased, especially at shorter wavelengths, by 2.5-fold with the krypton 
laser and by 1.5-fold with the cw-Nd:YAG laser. (Vogel et al. 1991) In non-contact applications, the scleral 
transmission is 24% for 670 nm, 36% for 810 nm, and 50% for 1064 nm. (Vogel et al. 1991) From the 
available data (Rol et al. 1990, Vogel et al. 1991) it can be extrapolated that, with the 670 nm laser using 
contact application and pressure on the sclera, 43% of the energy is transmitted and the rest is reflected, with 
little absorption by the sclera. The corresponding scleral transmission with contact application for the 810 
nm diode and the 1064 nm Nd:YAG laser is about 60%. (Rol et al. 1990, Vogel et al. 1991) On the other 
hand, the absorption of light by the pigment epithelium is 66% at 670 nm, as compared with 37% at 810 nm 
and 12% at 1064 nm, (Vassiliadis 1989) compensating for the poorer scleral transmission of the red 670 nm 
diode laser. Thus the energy of the red lasers, with high affinity for the pigment epithelium, is more 
selectively absorbed by the pars plicata than that of the infrared lasers. 
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Our previous experimental and clinical experience has suggested that the red krypton at 647 nm is a 
promising wavelength for transscleral CPC. (Immonen et al. 1993, Immonen et al. 1994) To produce 
comparable lesions in the pars plicata of the rabbit eye, the contact krypton laser requires only half of the 
energy that is needed with the contact cw-Nd:YAG laser. (Immonen et al. 1993) Although clinically similar 
IOP responses, with similar or smaller total energies per session, are obtained with the red lasers than with 
the infrared Nd:YAG laser, the poorer scleral transmission and better absorption by melanin with the red 
lasers indicates that less energy enters the eye with the red lasers, and even less energy reaches the vitreous 
and the retina at the contralateral wall of the eye. This may be of practical importance, since, in the case of 
non-contact Nd:YAG CPC, it has been calculated that the resulting retinal exposure to energy may even 
exceed the threshold for retinal damage. (Myers et al. 1998)  
The total energy applied with the red CPC is similar to that of the 810 nm diode CPC, but these two 
modalities differ in principle. In red laser CPC, the power at the scleral surface is 0.35 to 0.43 W and the 
duration of one laser exposure with the red CPC is 10 seconds. In the 810 nm diode CPC, the corresponding 
values are in the region of 1.5 to 2.0 W and 1.5 to 2.0 seconds. (Yap-Veloso et al. 1998, Flaxel et al. 1997, 
Oguri et al. 1998) From the powers mentioned above and the scleral reflectance values given by Rol et al. 
(Rol et al. 1990), it can be estimated that the amount of energy traversing the sclera during one CPC 
application is about 1.4 J/s with the 810 nm CPC, and 0.2 J/s with the 670 nm diode CPC.  
Further, the duration of the laser exposure with the red laser CPC, 10 seconds, is longer than in other 
modalities of transscleral laser CPC. This allows for the lower power of the laser, and explosive reactions in 
the ciliary body are avoided. On the other hand, the long duration allows more heat to be spread from the 
pigment epithelium to other parts of the ciliary body, resulting in less selective coagulation of the pigment 
epithelium than is suggested by the absorption characteristics of the wavelength used. However, the cooling 
effect of the highly vascularized ciliary body may limit the spreading of heat, especially at the very low 
intraocular power levels used in the red laser CPC.  
As a result of the low power and the long duration of application, parts of the ciliary body lesion may be 
warmed to levels above 43°C without being coagulated. Such a hyperthermic effect may induce apoptosis in 
the cellular components of the ciliary body (Mainster et al. 2000) instead of the necrosis that occurs after 
coagulative lesions. It is known that, as compared with necrotic cell death, the inflammatory reaction 
following apoptosis is minimal. (Papermaster et al. 1995, Mainster et al. 2000). The hyperthermia produced 
in the lesions by the low-power, slow-burn laser may partly explain the mild postoperative uveitis and the 
fact that pain is rarely observed after this treatment modality as compared with cyclocryocoagulation and 
Nd:YAG CPC. (Stewart et al. 1996, Jennings et al. 1999) 
 
 
6.2. Transscleral Cyclophotocoagulation with the Contact 
Krypton Laser for Treatment of Posttraumatic Glaucoma (I)  
In this study, the first krypton CPCs were performed a mean of 8.1 years (7 days to 30.5 years) after the 
initial ocular injury, which was an open globe injury in 56% of eyes and a contusion injury in 44% of eyes. 
Seventy-seven percent of patients had already undergone previous ocular surgery and glaucoma procedures 
had been done on 44% of the eyes before CPC. 
The IOP success rate (an IOP of 8 to 21 mmHg or a decrease in IOP > 30%) was 67%. All three eyes with 
pretreatment IOP < 22 mmHg maintained this IOP level after treatment, but none achieved greater than a 
30% IOP reduction. If these three eyes are classified as treatment failures, the success rate decreases to 50%. 
The heterogeneity of eyes in different studies makes comparison of the CPC outcomes difficult, but it 
appears that our result is within the 39% to 85% in some previously published studies of heterogeneous 
glaucoma populations after CPC. (Brancato et al. 1989, Hampton et al. 1990, Schuman et al. 1992, Al-
Ghamdi et al. 1993, Hawkins et al. 1993, Immonen et al. 1994, Brancato et al. 1995, Bloom et al. 1997, 
Wong et al. 1997, Werner et al. 1998, Spencer et al. 1999, Therkeld et al. 1999, Schlote et al. 2001b) The 
success of IOP after CPC tends to be lower in trauma patients than in an average glaucoma population: In a 
study of 93 eyes, Schlote et al. reported an IOP success rate of 54.5% for 14 trauma eyes compared with that 
of 90% for eyes with primary open-angle glaucoma. (Schlote et al. 2001b) In this study, after krypton CPC, 
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the mean IOP decreased by 40%. With the non-contact Nd:YAG CPC, Baez et al. (Baez et al. 1994) reported 
a decrease in mean IOP of 22% in posttraumatic glaucoma (n=8), which showed the least hypotensive effect 
in a study of 128 eyes. In that study, a decrease in mean IOP of 56% was achieved in neovascular glaucoma, 
although the posttraumatic patients required more treatment sessions per eye (3.6 treatments vs. 1.3 
treatments within 2 years). 
After contact 810 nm diode CPC, the mean percentage IOP reduction in posttraumatic glaucoma (n=14) 
was 33% in a study of 210 eyes, at the lower end of all the glaucoma subgroups included (29% in anterior 
dysgenesis to 53% in neovascular glaucoma) (Bloom et al. 1997). In contrast, in a study of 58 eyes, also with 
the 810 nm diode CPC, Spencer and Vernon obtained a reduction of 57% in mean IOP in trauma patients 
(n=5). (Spencer et al. 1999) They obtained a lower postoperative mean IOP in posttraumatic glaucoma 
compared with that of all treated eyes which may be due to the small number of trauma patients analyzed in 
their study.   
To reach an acceptable IOP, repeated CPC treatments were needed in 8 of the 18 eyes in the 
posttraumatic eyes (44%) in the present study. In a general glaucoma population evaluated by Bloom et al. 
(mean follow-up time 10 months), 102 of the 210 eyes (49%) were retreated, and in that of Immonen et al. 
(mean follow-up time 6 months), 8 of the 62 eyes (13%) were retreated. (Immonen et al. 1994, Bloom et al. 
1997) 
In posttraumatic glaucoma, conjunctival and scleral abnormalities may prevent incisional glaucoma 
surgery. The outcome of a filtration procedure (Mermoud et al. 1996) or implant surgery (Välimäki et al. 
1998) in traumatized eyes is modest, mainly because of the increased healing response due to intraocular 
inflammation, previous intraocular operations, and the young age of trauma patients. Vitreous incarceration 
into the filtering site or at the tube in a posttraumatic aphakic eye may also block the outflow. In filtration 
surgery without antimetabolites, the cumulative probability of survival in angle-recession glaucoma was 52% 
at 1 year, 32% at 3 years, and 8% at 5 years. (Mermoud et al. 1993a)  
In angle-recession glaucoma, trabeculectomy with antimetabolites resulted in more successful cases at 3 
and 6 months than trabeculectomy without antimetabolites or Molteno implantation. (Mermoud et al. 1993b) 
The mean reduction in IOP was also largest in the antimetabolite group (59% as compared with 36% and 
41%). However, when the surgical outcome for each operation was compared, using the log-rank test, no 
statistically significant difference was found. In 15% of patients treated with 5-fluorouracil or mitomycin C, 
there were severe bleb-associated complications as compared with 0% after trabeculectomy and 0% after 
implant surgery. (Mermoud et al. 1993b) 
The IOP results in the present study and those of eyes with angle-recession glaucoma only cannot be 
directly compared (Mermoud et al. 1993b, Mermoud et al. 1993a), as, in the latter studies, eyes with partial 
or total dislocation of the lens and eyes with angle closure due to peripheral anterior synechiae had been 
excluded. Most of the patients in our study had suffered from open globe injuries with multiple 
reconstructive procedures subsequently. 
In the present study, the median number of topical glaucoma preparations, preoperatively was 2 and at the 
last control visit, 1. The median daily dose of CAI and the proportion of patients taking it was reduced during 
the follow-up. This reduction did not reach statistical significance. In the literature, there are no available 
data concerning the change in medical therapy of posttraumatic patients only, but our result is in accord with 
the results reported by Schlote 2001b et al. for 810 nm diode CPC in a general glaucoma population. 
(Schlote 2001b et al.) As in the present study, patients were able to discontinue CAI after 810 nm diode 
CPC. (Bloom et al. 1997, Mistlberger et al. 2001) The mean total number of glaucoma medications was 
reduced in some studies of 810 nm diode CPC (Kosoko et al. 1996, Wong et al. 1997, Werner et al. 1998, 
Yap-Veloso 1998, Spencer et al. 1999, Therkeld et al. 1999, Pucci et al. 2001). In some studies made after 
Nd:YAG CPC in a general glaucoma population, the mean number of medications was reduced, but the 
statistical significance of the change was not always tested (Brancato et al. 1989, Hampton et al. 1990, Trope 
and Ma 1990, Al-Ghamdi et al. 1993, Hennis et al. 1993) In some reports the number of medications 
remained unchanged. (Hawkins et al. 1993) However, after filtering and implant surgery in angle-recession 
glaucoma, the need for additional glaucoma medication was statistically significantly reduced. (Mermoud et 
al. 1993b, Mermoud et al. 1993a) 
 In the present study, 3 of 18 eyes (17%) showed a decline in VA after a mean follow-up time of 19.4 
months. We consider the visual loss in 2 eyes to be potentially CPC-related. After Nd:YAG CPC, using 
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varying criteria, VA decreased in 7% to 65% of eyes. (Trope et al. 1990, Schuman et al. 1992, Al-Ghamdi et 
al. 1993, Shields et al. 1993, Baez et al. 1994, Shields et al. 1994, Dickens et al. 1995, Zhou Wei et al. 1996, 
Youn et al. 1998) Similarly, after 810 nm diode CPC, 18.7% to 38% lost vision. (Yap-Veloso et al. 1998, 
Youn et al. 1998, Spencer et al. 1999, Mistlberger et al. 2001) Studies indicate that postoperative visual loss 
after Nd:YAG CPC is correlated with hypotonia, neovascular glaucoma and a long follow-up time. 
(Schuman et al. 1992, Youn et al. 1996). After filtering or implant surgery with or without antimetabolites, 
26% of posttraumatic patients had a decrease in vision. (Mermoud et al. 1993b) 
In the present study, one patient (6%) developed phthisis bulbi, but only 2 years and 2 months after the 
last CPC and 5 months after complicated cataract surgery, before which the IOP had been within the normal 
range. No other patient ended up with an IOP permanently less than 6 mmHg. In the series of Immonen et al. 
(Immonen et al. 1994), hypotonia (4 mmHg < IOP < 8mmHg) was seen in 4% and phthisis bulbi in no eyes 
treated with krypton laser CPC.  
After 810 nm diode laser CPC, hypotonia was reported in 0% to 15% and phthisis in 0% to 2%. (Hawkins 
et al. 1993, Kosoko et al. 1996, Yap-Veloso et al. 1998, Youn et al. 1998, Spencer et al. 1999, Walland 2000, 
Schlote et al. 2001b) After Nd:YAG CPC, hypotonia rates of 0% to 15%, (Schuman et al. 1990c, Al-Ghamdi 
et al. 1993, Shields et al. 1993, Shields et al. 1994) and rates of phthisis bulbi of 0% to 11% (Trope et al. 
1990, Schuman et al. 1992, Shields et al. 1993, Baez et al. 1994, Shields et al. 1994, Dickens et al. 1995, 
Zhou Wei et al. 1996 Threlkeld et al. 1999) have been reported in a general glaucoma population. After 
glaucoma implant surgery, 0% to 6% developed phthisis. (Lloyd et al. 1992, Noureddin et al. 1992, Lloyd et 
al. 1994, Krishna et al. 2001) 
In the present study, postoperative inflammation was mild. The eyes appeared reasonably unaffected with 
no signs of conjunctival injury. In one patient, scleral thinning was found on the treatment area after the third 
CPC. No significant postoperative pain, fibrinoid reactions, intraocular haemorrhages, or permanent 
posterior segment complications were detected. 
 
  
6.3. Transscleral Cyclophotocoagulation with the Contact 
Krypton Laser for Treatment of Glaucoma in Children and Young 
Adults (II)  
In young glaucoma patients, medical glaucoma treatment has only a limited effect. Surgical treatment 
options include goniotomy, trabeculotomy, trabeculectomy, or combined trabeculotomy-trabeculectomy. 
(Luntz 1996, Costa et al. 1993) The success of filtration and implant surgery (Munoz et al. 1991, Hill et al. 
1991, Eid 1997a) is lowered by the thick Tenon´s capsule, the strong healing response, and, in some patients, 
by scarring of the conjunctiva after previous operations. (Beauchamp et al. 1979, Stürmer et al. 1993) 
Performing a glaucoma filtration procedure or implant surgery in buphthalmic eyes is complicated by the 
stretching and thinning of the coats of the eye, the low scleral rigidity, and the failure of the stretched zonules 
to provide a normal suspension for the lens or support for the vitreous. (Beauchamp et al. 1979) Previous 
ocular operations resulting in conjunctival adherence to the sclera also carry a worse prognosis for a 
successful filtering bleb. (Beauchamp et al. 1979, Stürmer et al. 1993)  
Trabeculectomy with antimetabolites is performed in children in eyes in which conventional procedures 
have failed, but also as a primary procedure. (Susanna et al. 1995, Mandal et al. 1997, Beck et al. 1998, Al-
Hazmi et al. 1999) When previous incisional surgery has failed or in cases considered unlikely to be 
controlled with other treatment modalities, transscleral CPC (Phelan et al. 1995, Bock et al. 1997, Izgi et al. 
2001, Kirwan et al. 2002) and endoscopic CPC (Neely et al. 2001, Barkana et al. 2002) have been 
performed.  
Twenty of 22 eyes in this series had difficult secondary glaucoma. In these eyes, 21 unsuccessful filtering 
and/or implant glaucoma operations and revisions, and 16 other intraocular operations had already been 
performed before the krypton CPC. 
After one or more krypton CPC treatments, an IOP of  8 to 21 mmHg was obtained in nine (41%) and an 
IOP of  8 to 21 mmHg or a reduction in IOP of > 30% in 14 (64%) of 22 eyes at the last follow-up visit. Our 
IOP success rate is comparable with that of most previous studies in young patients, but lower than that of 
Discussion 
 54 
most adult series treated with CPC. (Phelan et al. 1995, Bock et al. 1997, Immonen et al. 1994, Youn et al. 
1996, Bloom et al. 1997, Kirwan et al. 2002) The better outcome in the adult population implies that 
paediatric patients are less responsive to CPC treatment. However, Izgi et al. found no statistically difference 
in the IOP survival rate between adult (n=26) and paediatric (n=15) glaucoma patients after 810 nm diode 
CPC, but the number of eyes in that study may have been small for the purpose of comparison. (Izgi et al. 
2001) 
In children, repeated treatments were needed in 64% of the eyes in the present study and in 56% to 70%  
of the eyes in other studies. (Phelan et al. 1995, Bock et al. 1997, Kirwan et al. 2002) Retreatments are 
needed less often in adults, for only 13% of the eyes were retreated in the study of adult glaucoma by 
Immonen et al., using the krypton laser, and in 49% of the eyes in the study of Bloom et al. (Bloom et al. 
1997), using the 810 nm diode laser. Izgi et al. found no significant difference in the retreatment rate 
between paediatric patients and adults, but, again, the numbers in that study may have been small for the 
purpose of comparison. (Izgi et al. 2001) 
Irrespective of the surgical modality used (CPC, filtration or implant surgery), the treatment of glaucoma 
in children and young adults is challenging. Although higher success rates have been reported in selected 
series (mainly in those of primary glaucomas), success rates obtained in unselected paediatric populations are 
in the same range irrespective of the treatment modality used (Table 2). (Beauchamp et al. 1979, Hill et al. 
1991, Munoz et al. 1991, Lloyd et al. 1992, Stürmer et al. 1993, Susanna et al. 1995, Eid et al. 1997a, 
Mandal et al. 1997, Al-Hazmi et al. 1998, Beck et al. 1998)  
In the present study, there was a statistically significant reduction in the number of eyes using glaucoma 
medication at the last follow-up visit compared to baseline, but the median number of topical glaucoma 
medications pre- and postoperatively was 2. The mean number of medications was statistically significantly 
reduced in the study of Izgi et al. (Izgi et al. 2001), but others reported that CPC did not enable reduction of 
the number of medications in childhood glaucoma. (Phelan et al. 1995, Bock et al. 1997, Kirwan et al. 2002) 
In the present study, VA decreased by more than two Snellen lines or there was a change in the low 
vision category in 18% of eyes during the follow-up time. In view of the severity of the multiple concomitant 
conditions in these eyes, it is difficult to decide how far CPC was responsible for the observed decline in VA. 
Izgi et al. found no VA decrease after CPC in paediatric glaucoma, but most of the eyes in his study had 
congenital glaucoma. (Izgi et al. 2001) In the study by Kirwan et al., also comprising fewer cases of 
secondary glaucoma than our study, 8% lost vision after CPC. (Kirwan et al. 2002)  
In young patients, the interpretation of the effect of CPC is complicated by the imprecise nature of VA 
measurement, especially at the low levels of vision, and visual maturation during follow-up. (Izgi et al. 2001, 
Kirwan et al. 2002) After the contact 810 nm diode CPC for paediatric glaucoma, Bock et al. noted a decline 
in vision in 4 (18%) of 22 eyes and Phelan et al., after using the contact Nd:YAG laser, noted a decline in 4 
(40%) of 10 eyes. (Phelan et al. 1995, Bock et al. 1997) 
In the present study, no eyes ended up in permanent hypotonia or phthisis bulbi. In other paediatric 
glaucoma series, using a 810 nm contact diode laser, phthisis was reported in 0% (Izgi et al. 2001), 4% 
(Kirwan et al. 2002), and 5% (Bock et al. 1997), and, using a contact Nd:YAG laser, in 10%. (Phelan et al. 
1995) The absence of chronic hypotonia and phthisis in our series may be due to the fact that, even in 
patients with multiple treatment sessions, we generally avoided treating 360° of the ciliary body. 
In our study, postoperative inflammation was mostly mild. There was no significant postoperative pain 
requiring systemic analgesics, or intraocular haemorrhages, or permanent complications in the posterior 
segment. The eyes appeared reasonably unaffected, except those with chronic uveitis, which required more 
postoperative cortisone eye drops. No signs of conjunctival injury were detected. Scleral thinning developed 
in two eyes: one of these had received one CPC at a distance of 4 mm from the limbus (with obvious 
incorrect localization of the pars plicata region) in the pars plana, where the pigment epithelium is closer to 
the sclera than in the pars plicata, probably thus contributing to absorption of more energy by the sclera. The 
other eye was a microphthalmic aphakic eye treated with CPC at a distance of 1.5 mm from the limbus. 
Possibly, anterior segment anomalies in this eye contributed to the abnormal scleral absorption of the laser 
energy. No reports comparing the penetration and absorption of laser energy through the human eye in 
children are available, but focal scleral thinning was also detected earlier in a 30-year-old man treated with 
the Nd:YAG laser CPC.  (Fiore et al. 1989) More recently, scleral perforation was reported after 810 nm 
contact CPC in an eye with scleral thinning following cataract surgery. (Sabri et al. 1999) 
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In other studies of CPC in young patients, postoperative complications were also few. (Kirwan et al. 
2002,  Phelan et al. 1995, Izgi et al. 2001, Bock et al. 1997) However, retinal detachment and subsequent 
phthisis in the majority of the same cases were discovered in 4% to 10%. (Kirwan et al. 2002,  Phelan et al. 
1995, Izgi et al. 2001, Bock et al. 1997) Kirwan et al. further repored that two of the three paediatric patients 
with postoperative retinal detachment had previously been treated with Nd:YAG CPC. In adults, retinal 
detachment is a known complication of Nd:YAG CPC. (Geyer et al. 1993) 
 
 
6.4. Transscleral Cyclophotocoagulation with the Red Laser 
Combined with Limited Anterior Retinal Cryocoagulation in 
Neovascular Glaucoma (III) 
In neovascular glaucoma, there is no ideal surgical procedure. (Sivak-Callott et al. 2001) Despite successful 
control of IOP, the visual prognosis remains poor because of the severe underlying disease process. The 
patients with neovascular glaucoma in this study were of advanced age (mean, 75.0 years) with high 
preoperative IOPs (mean, 44.0 mmHg) and poor VA (unrecordable with the Snellen charts in 90% of the 
patients). In the majority (77%) of the eyes, neovascular glaucoma was caused by a previous occlusion of the 
central retinal vein. In 19 eyes, the combined procedure was performed to achieve an IOP within the normal 
range and to preserve vision. In 11 eyes, it was performed to decrease the IOP to a tolerable level and relieve 
ocular pain in an eye with no visual potential. 
6.4.1. Retinal Cryocoagulation 
In the management of neovascular glaucoma, the cornerstone is retinal panphotocoagulation. (Krill et al. 
1971, Laatikainen 1977, Flanagan et al. 1983). Transpupillary retinal photocoagulation can be performed 
with a slit-lamp delivery system or with indirect ophthalmoscopy. If media opacities or retinal haemorrhages 
are present, the 647 nm krypton laser and the 810 nm diode laser will frequently be more effective than the 
argon laser. (Wand 1996)  
In eyes with neovascular glaucoma, fundus visibility is often decreased because of corneal 
decompensation, poor mydriasis, cataract, and/or vitreous haemorrhage, which prevent transpupillary laser 
treatment of the retina. (Lloyd et al. 1991, Mermoud et al. 1993c, Tsai et al. 1996, Flaxel et al. 1997) In cases 
of inadequate visualization, transscleral anterior retinal cryocoagulation (Sihota et al. 1991, Knapp et al. 
1997) and transscleral retinal photocoagulation (Tsai et al. 1996, Flaxel et al. 1997) are viable treatment 
options. Preoperatively in this study, it had been possible to perform transpupillary retinal 
panphotocoagulation in only 23% of eyes, but, even in these eyes, active iris neovascularization persisted. 
Thus, the only means of decreasing the ischaemic stimulus was considered to be transscleral cryocoagulation 
of the anterior retina. 
Retinal cryocoagulation is known to induce more breakdown of the blood-retinal barrier than retinal laser 
photocoagulation (Jaccoma et al. 1985, Inoue et al. 2001), especially if the freezing time is long or if the 
same site is frozen repeatedly. (Singh et al. 1986) Excessive breakdown of the blood-eye barrier is connected 
with fibrinoid reactions and proliferative vitreoretinopathy. To minimize these reactions, we limited the 
number of applications to 15 to 40 per treatment and set the applications no further than 1 to 2 rows behind 
the ora serrata. In 93%, fundus visibility was sufficient for ophthalmoscopic monitoring of the retinal 
freezing, which was interrupted at the first sign of retinal blanching. 
6.4.2. Outcome of the combined procedure  
In this study, the decrease in mean IOP of 50% was comparable with that of other transscleral laser CPC 
modalities in neovascular glaucoma (Table 3). In the published studies, the IOP success rates have ranged 
from 33% to 86%. It is difficult to compare these results with those of the present study, because of the 
Discussion 
 56 
differences in the patient characteristics and the definition of IOP success. It appears, however, that the IOP 
successes with the combined procedure with the krypton and 670 nm diode lasers in our study, 62% and 71% 
(using a definition of IOP < 22 mmHg for the purpose of comparison) and in particular those of the 
therapeutic group, 86% and 92%, are high compared with those published for the CPC in neovascular 
glaucoma (Table 3). The IOP responses in the krypton laser and the 670 nm diode laser groups were equal, 
but the retreatment rate was higher in the 670 nm diode group. In 43% of cases, iris neovascularization 
regressed or disappeared. 
In a study by Flaxel et al., transscleral retinal 810 nm diode laser photocoagulation was combined with 
the 810 nm diode laser CPC, and an IOP of < 22 mmHg was obtained in six out of nine eyes and hypotonia 
developed (IOP of 0 to 2 mmHg) in three eyes. (Flaxel et al. 1997) All eyes showed regression of rubeosis, 
and one eye showed complete resolution of rubeosis. In both the two eyes treated similarly by Tsai et al., an 
IOP of < 22 mmHg and the regression of rubeosis was achieved in both eyes. (Tsai et al. 1996) 
In neovascular glaucoma, filtration surgery has a poor chance of success unless the stimulus for new 
vessel formation is eliminated. (Wand 1996) Studies on filtration and implant surgery in neovascular 
glaucoma show success rates of 35% to 67% (Table 4, Allen et al. 1982, Minckler et al. 1988, Lloyd et al. 
1991, Mermoud et al. 1993c, Tsai et al. 1995) but also a high incidence of visual decrease (up to 62%) and 
phthisis (up to 24%). Tube surgery compared favourably with the non-contact Nd:YAG CPC (360° treatment 
in 83% of the eyes) in terms of IOP control (the mean final reduction in IOP in the two groups was equal), 
visual outcome (baseline VA was significantly worse in the CPC group), and hypotonia (3/24 eyes in the 
tube surgery group vs. 6/24 eyes in the CPC group) in neovascular glaucoma. (Eid et al. 1997b) Randomized 
clinical comparisons of tube surgery and contact CPC with other laser modalities are not as yet available. 
In the present study, the reduction in use of CAI after treatment was statistically significant. At the last 
follow-up, one patient (3%), as compared with eight (27%) at baseline, was using peroral CAI. During 
follow-up, the median number of topical glaucoma medications was also reduced from 2.0 to 1.0 in both 
laser treatment groups, but this reduction was not statistically significant. After fr-YAG (n=9), cw-YAG 
(n=9), or 810 nm diode (n=21) CPC in neovascular glaucoma eyes only, Oguri reported a result similar to 
ours. (Oguri et al. 1998) However, use of CAI was not separately reported in that study.  
In our study, VA decreased during the follow-up time in 15 (50%) of 30 eyes and, of these, seven eyes 
progressed to no light perception. The reasons for the decrease in vision were a high IOP and progression of 
the retinal disease in seven eyes with no visual potential, in which the treatment was palliative. In the eight 
eyes in which the treatment was therapeutic, the causes of visual deterioration were progression of the retinal 
disease (five eyes), progression of cataract (two eyes), and vitreous haemorrhage with intermittent high IOP 
(one eye). Thus, the decline in vision seemed not to be treatment-related in our study. This is in agreement 
with the results of Egbert et al. in eyes with primary open-angle glaucoma. (Egbert et al. 2001) In their study, 
they found equal rates of visual decrease (23%) in the eyes after primary 810 nm diode CPC and in the 
control fellow eyes that were receiving medical therapy only. Similarly, in the study of Hamard et al., a 
decrease in VA, noted in 34% of eyes treated with 810 nm diode CPC, was not related to cyclodestruction. 
(Hamard et al. 1997) In the present study, VA was very poor preoperatively (unrecordable with the Snellen 
charts in 90% of the patients), which may have caused fluctuation and unreliability in visual testing.  
After Nd:YAG CPC, the decrease in VA was shown to be high, up to 56%, in eyes with neovascular 
glaucoma, partly as a result of hypotonia and phthisis. (Hampton et al. 1990, Schuman et al. 1992, Youn et 
al. 1996) In the study of Oguri et al. (Oguri et al. 1998) in neovascular glaucomatous eyes treated with the 
810 nm diode CPC, 24% lost vision. An additional 14% of the eyes in that study already had no light 
perception at baseline. Studies of filtration and implant surgery in neovascular glaucoma also show a high 
incidence of visual decrease, up to 62% (Table 4). (Allen et al. 1982, Minckler et al. 1988, Lloyd et al. 1991, 
Mermoud et al. 1993c, Tsai et al. 1995)  
In the present study, only one eye (3%) developed phthisis 39 months after the CPC and another eye had 
an IOP of 5 mmHg at the last follow-up visit. This low incidence of hypotonia and phthisis may be due to the 
fact that, even after multiple treatments, we generally left one quadrant of the ciliary body untreated. Most 
complications after treatment were mild and transient (Table 22). Hypotonia and phthisis are well-known 
complications of cyclodestructive treatments, described especially after cyclocryotherapy (Klemm et al. 
1995, Heuring et al. 1998) and Nd:YAG CPC. With the contact or non-contact Nd:YAG CPC, phthisis bulbi 
of up to 19% have been reported in neovascular glaucoma (Table 3) (Trope et al. 1990, Schuman et al. 1992, 
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Shields et al. 1994, Youn et al. 1996), but neovascular glaucoma was also shown to be an independent risk 
factor for these complications. (Hampton et al. 1990, Schuman et al. 1992, Youn et al. 1996) After filtration 
and implant surgery in neovascular glaucoma, phthisis was reported in 0% to 24% of eyes. (Table 4) 
 
 
6.5. Corneal Innervation, Corneal Mechanical Sensitivity, and 
Tear Fluid Secretion after Transscleral Cyclophotocoagulation 
with the Contact 670 nm Diode Laser (IV)   
6.5.1. In vivo confocal microscopy 
After 670 nm diode laser CPC, sequential in vivo confocal microscopic examinations of the subbasal nerve 
plexus in the central and inferior limbal areas of the three corneas studied, at the level of resolution allowed 
by the methodology, did not reveal any significant reduction in nerve density. However, it should be noted 
that with in vivo confocal microscopy, bundles of nerve fibres are viewed, rather than single fibres (Müller et 
al. 1996, Müller et al. 1997), and, therefore, with this technique, the absence of single nerve fibres among the 
bundles cannot be discerned. The confocal microscopic examination can also be criticised for the fact that 
only a very limited area of the cornea (360 µm x 450 µm) can be evaluated at one time. As most of the 
stromal nerves run obliquely to the surface and cannot be easily visualized by in vivo confocal microscopy, 
stromal nerve density was not evaluated.  
Before treatment, the patients already showed a reduced number of subbasal nerve fibre bundles, which 
may have been due to their advanced age. The confocal microscopic images of the subbasal nerves in the 
healthy cornea, published earlier, represent those of younger individuals. (Rosenberg et al. 2000b, 
Vesaluoma et al. 2000) Glaucoma and the prolonged use of glaucoma medication can also be speculated to 
have played a role. However, none of the three patients examined by confocal microscopy had undergone 
any previous intraocular surgical procedures or transscleral treatments that would have affected the corneal 
nerves. 
Bearing in mind the limitations of the confocal microscopic technique, we conclude that our present 
findings concerning the corneal nerves are in accord with those previously reported by Johnson et al. 
(Johnson et al. 1999). Using anticholinesterase staining, Johnson et al. did not find any quantitative 
histological changes in corneal nerve density after the 810 nm diode laser CPC in a rabbit model. However, 
qualitative changes in the structure of the nerve fibres were revealed in their study by transmission electron 
microscopy: The 810 nm diode laser CPC appeared to cause disruption of the myelin nerve sheaths, and 
damaged keratocytes were also observed in the tissue samples. We did not detect any keratocyte activation or 
particular damage to the keratocytes in the central cornea by in vivo confocal microscopy after 670 nm diode 
laser CPC.  
 
6.5.2. Corneal sensitivity and tear fluid secretion 
 
Comparison of the pre- and postoperative data for each corneal area in each individual eye showed that there 
were no statistically significant changes in the mechanical sensitivity values in any of the corneal areas 
examined.  
Since tear secretion is under neural control, (Dartt 1994, Meneray et al. 1998) we expected that, if CPC 
induced a sensory deficit, the amount of the basic tear secretion would diminish, as was shown to happen 
after laser in situ keratomileusis (LASIK) by Yu et al. (Yu et al. 2000) Of our patients, two had changed to a 
higher Schirmer value category. Four of our patients had changed to a lower Schirmer value category, but, in 
the cornea next to the treated part of the ciliary body, the sensitivity remained unchanged. There was no 
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systematic trend towards worsening of the Schirmer value, and since the Schirmer basic secretion tear test 
excludes reflex tear production, it might be expected that the variability of these results would be less than 
that of the total secretion.  
The clinical course of the eyes studied was unremarkable. Patient 3 showed transient corneal punctate 
staining with fluorescein at 3 days, but no reduction in tear fluid secretion, no deterioration in corneal 
sensitivity, and no change in the corneal subbasal nerves during follow-up.  
Given the small sample size in this investigation, further controlled studies with larger numbers of 
patients are desirable to definitively rule out the possibility of corneal nerve damage after transscleral contact 
670 nm diode CPC.     
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7. Summary and conclusions 
Today, it appears reasonable to consider that, in addition to destroying the epithelium and capillaries of the 
ciliary processes (Marsh et al. 1993), cyclodestruction contributes to the increase in uveoscleral outflow of 
aqueous humour due to loss of the blood-aqueous barrier within the laser-induced scar. (Schubert 1989a, 
Schubert 1990, Liu et al. 1994) The results of this study reveal the outcome of transscleral red laser CPC in 
therapy-resistant glaucoma. The protocol with low laser power and a long duration of application diverges 
from the other treatments commonly used for CPC. In transscleral cyclophotocoagulation, the importance of 
careful peroperative localization of the pars plicata, using scleral transillumination must be stressed.  
The study comprised the patients with therapy-resistant posttraumatic glaucoma who were treated with 
krypton red laser CPC at the Department of Ophthalmology, Helsinki University Eye Hospital, the aim being 
to evaluate the usefulness and complications of this procedure in posttraumatic glaucoma. There were 
altogether 18 eyes of 18 patients, aged 56.6 ± 23.0 years. The indication for CPC was uncontrolled glaucoma 
despite maximal tolerated medication. The procedure was performed as an alternative to filtration or implant 
glaucoma surgery. Follow-up data were gathered in a retrospective chart review. After one or more krypton 
CPCs, but no other glaucoma procedures, the mean IOP decreased by 40% from the preoperative level of 
32.6 ± 12.8 mmHg to 19.6 ± 10.5 mmHg at the last control visit 19.4 ± 21.2 months postoperatively. The 
IOP success rate (an IOP of 8 to 21 mmHg or a decrease in IOP > 30%) was 67%. There were three eyes 
with pretreatment IOP < 22 mmHg which all maintained this IOP level after treatment, but none achieved 
greater than a 30% IOP reduction. If these three eyes are classified as treatment failures, the success rate 
decreases to 50%. This is within the success rates of CPC published of heterogeneous glaucoma populations. 
Repeated treatments were needed in 44% of eyes. The median number of topical glaucoma medications and 
the median daily dose of CAI was reduced during follow-up but the reduction did not reach statistical 
significance. Seventeen percent of eyes showed a decline in VA. One (6%) case of phthisis occurred. The 
results of this study suggest that transscleral krypton red laser CPC is a useful procedure for lowering IOP in 
posttraumatic glaucoma. It is reasonably safe for the eye and can be repeated when necessary. 
Patients under 20 years of age with therapy-resistant glaucoma treated with the krypton red laser CPC at 
the Department of Ophthalmology, Helsinki University Eye Hospital, were included in the study to evaluate 
the usefulness and complications of the procedure in children and young adults with glaucoma. The study 
comprised 22 eyes of 22 patients, aged 10.5 ± 5.6 years. The indication for cyclophotocoagulation was 
uncontrolled glaucoma despite maximal tolerated medication. The procedure was performed as an alternative 
to filtration or implant glaucoma surgery. Follow-up data were gathered in a retrospective chart review. After 
one or more krypton CPC treatments, the mean IOP decreased by 25% from a preoperative level of 35.0 
± 7.9 to 26.2 ± 10.5 mmHg at the last control visit 27.1 ±  21.9 months postoperatively. IOPs of  8 to 21 
mmHg were obtained in 41% and the IOP success rate (an IOP of 8 to 21 mmHg or a decrease in IOP of > 
30%) at the last follow-up visit was 64%. Our IOP result is comparable with that of most previous studies in 
young patients, but lower than in most adult series treated with CPC. Success rates similar to ours have been 
obtained in unselected paediatric populations independently of the surgical treatment modality used. 
Repeated treatments were needed in 64% of the eyes. The number of patients using glaucoma medication at 
the last follow-up visit was reduced compared to the baseline (P < 0.05). VA decreased in 18% of eyes 
during the follow-up time. No permanent hypotonia, phthisis bulbi, or devastating CPC-related 
complications were noted. The results of this study suggest that the transscleral krypton red laser CPC is a 
reasonably safe procedure for lowering IOP in children and young adults with difficult glaucomas, but that 
multiple treatments may be needed.  
Patients with therapy-resistant neovascular glaucoma treated with the krypton red laser (13 patients) or 
the 670 nm diode laser (17 patients) CPC followed by anterior retinal cryocoagulation at the Department of 
Ophthalmology, Helsinki University Eye Hospital, were included in the study to evaluate the usefulness and 
complications of this combined procedure in neovascular glaucoma. The study comprised 30 eyes of 30 
patients, aged 75.0 ± 12.1 years. The indication for CPC was uncontrolled glaucoma despite maximal 
tolerated medication. The CPC was performed as an alternative to filtration or implant glaucoma surgery. 
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The indication for retinal cryocoagulation was retinal ischaemia, as demonstrated by iris neovascularization, 
and persisting after full panphotocoagulation or found to be untreatable by transpupillary 
panphotocoagulation. In 11 eyes with no visual potential, the combined treatment was performed to relieve 
pain (palliative group). In 19 eyes the treatment was performed to preserve vision (therapeutic group). 
Follow-up data were gathered in a retrospective chart review. After one or more CPC treatments and one 
retinal cryocoagulation, the mean IOP at the last follow-up 16.8 ± 13.8 months postoperatively had 
decreased by 50% from the preoperative level of 44.0 ± 12.5 mmHg to 22.1 ± 15.8 mmHg. In the therapeutic 
group, an IOP of 8 to 21 mmHg was obtained in 79% of eyes. The IOP success rate (an IOP of  8 to 21 
mmHg or a decrease in IOP of more than 30%) for all eyes was 87% and, that for the therapeutic group, 
95%. These IOP successes with the krypton and the 670 nm diode red laser in our study are high compared 
with those published for CPC with other laser modalities or those for filtration and implant surgery in 
neovascular glaucoma. The IOP responses in the krypton laser and the 670 nm diode laser groups were 
equal, but the retreatment rate was higher in the 670 nm diode group. Repeated CPC treatments were needed 
in 27% of the eyes. In 43% of cases, iris neovascularization regressed or disappeared. At the last follow-up, 
3% of patients, as compared with 27% at baseline, was using peroral CAI (P < 0.05). VA decreased in 50% 
of all eyes and in 42% of the eyes with a therapeutic treatment indication. At the last follow-up, there was 
one case (3%) of hypotonia and one case (3%) of phthisis. The results of this study suggest that, in 
neovascular glaucoma, transscleral contact krypton or 670 nm diode red laser CPC combined with 
transscleral limited anterior retinal cryocoagulation is an efficient means for lowering the IOP and inducing 
regression of iris neovascularization. During the follow-up, the underlying retinal disease causes a decrease 
in VA in a significant proportion of patients. 
Ten patients with therapy-resistant glaucoma enrolled for 670 nm diode laser CPC at the Department of 
Ophthalmology, Helsinki University Eye Hospital, were included in the study to investigate whether the 670 
nm diode red laser CPC has an effect on corneal morphology and the density of corneal subbasal nerves as 
studied by in vivo confocal microscopy, on corneal mechanical sensitivity, and on the rate of tear fluid 
secretion. The study comprised 10 eyes of 10 patients aged 73.8  ± 6.4 years. The CPC was performed as an 
alternative to filtration or implant glaucoma surgery. Follow-up data were gathered prospectively. In vivo 
confocal microscopy, with special attention to corneal morphology and the density of the subbasal nerves in 
the central and inferior perilimbal cornea, was performed in three eyes preoperatively, and at 3 days, and 1 
month postoperatively. Corneal mechanical sensitivity was tested in all eyes preoperatively, and at 3 days, 
and at 1 month postoperatively, using a Cochet-Bonnet aesthesiometer. The rate of tear fluid secretion was 
measured in all eyes preoperatively and 1 month postoperatively, using the Schirmer basic secretion tear test. 
After treatment, in vivo confocal microscopy did not reveal any changes in any of the corneal layers or in the 
corneal subbasal nerves, nor was there any statistically significant change in the mechanical sensitivity 
values in any part of the cornea or in the Schirmer basic secretion tear test result (paired samples t test, P > 
0.05). The results of this study suggest that transscleral CPC with the 670 nm diode red laser does not impair 
corneal innervation.  
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